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ABSTRACT 
 
The research work described in this thesis concerns metal-based 
anticancer drugs with an emphasis on non-covalent DNA-binding 
supramolecular assemblies.  
 
The project involves the preparation of a series of mono- and bi-metallic 
ruthenium complexes with a primary focus on fluorescent dinuclear triple-
stranded helicates with different structural topographies. Emphasis is then 
directed towards an investigation of the DNA binding characteristics of these 
molecules and an evaluation of their anticancer properties in human cancer cell 
lines. Attention is brought to the significance that the cylinder-building moieties 
and their structural characteristics have to these features.  
The studies also include an examination of the effects of chirality of the 
investigated supramolecular systems and the impact they have on molecular 
recognition. This is addressed via studies of the interaction of optical isomers of 
ruthenium triple-stranded helicates with DNA as a biomolecular target system 
and with Δ-TRISPHAT as a representative small chiral molecule.  
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Introduction 
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1.1 DNA structures and properties  
DNA is a key biomolecule, which encodes genetic information essential 
to create and control living systems. This code begins to be processed when 
unwinding of the DNA helix is promoted and the DNA strands serve as 
templates to construct complementary molecules of messenger RNA in the 
process of transcription. The information contained in RNA is then ‘decoded’ 
and used for the synthesis of particular combinations of amino-acids to further 
manufacture proteins. The gene expression is mostly regulated by particular 
proteins, which bind non-covalently and reversibly to the DNA mainly through 
specific subunits like helix-turn-helix, leucine zippers or zinc finger motifs.[1] 
DNA is a very attractive medicinal target for small molecules, because 
interfering with DNA transactions such as replication or transcription or with 
DNA-protein interactions can lead to control of gene expression and thus 
potentially control diseases.  
 
1.1.1 B-DNA structure 
B-DNA is built of two inter-twined polynucleotide strands (Fig. 1.1). 
These strands consist of nucleobases (adenine A, guanine G, cytosine, C and 
thymine, T) bound to 2’-deoxyribose sugars, which in turn are held together by 
phosphodiester bonds.[1, 2] 
 
 
 
Fig. 1.1 Chemical structure of polynucleotide 
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The two anionic polynucleotide strands assemble into a helix spontaneously in 
a self-assembly process, which is assisted by hydrophobic interactions, 
hydrogen bonding between the complementary bases from the opposite, 
antiparallel strands (A -T and G-C) (Fig. 1.2) and π-π stacking between the 
adjacent base pairs.  
 
 
 
Fig. 1.2 Hydrogen bonding between the complementary DNA bases 
 
 
This in turn results in the formation of a helical arrangement, where the two 
strands are coiled around each other with the hydrophilic sugars placed outside 
the helix and hydrophobic bases inside (Fig. 1.3).  
 
Fig. 1.3 Structure of Watson-Crick DNA double helix 
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There are two different grooves in the B-DNA structure, named major and minor 
groove, which differ in size and depth. The B form of DNA is the main form 
found in cells, however under different conditions DNA may exist in a wide 
variety of different possible topologies such as left handed and multiple-
stranded helices.[3] This includes Z-DNA (left handed DNA), the dehydrated     
A-DNA, but also multiplexes and branched structures such as three-[4] or four-
way junctions (Fig. 1.4),[5-7] which are key intermediates in principal cellular 
processes such as transcription or replication. 
 
Fig.1.4 Structure of DNA Holiday junction (PDB ref. 1ZF2)[7] 
 
 
1.2 Metallo-anticancer drugs 
Metal complexes have a great potential for pharmaceutical use due to 
their wide range of coordination geometries, electronic properties and a variety 
of oxidation states. They have been investigated for clinical applications in a 
broad range of medicinal disciplines as MRI contrast agents, 
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radiopharmaceuticals, antibacterial agents, superoxide dismutase mimics, 
antidiabetic or anticancer drugs.[8-10] 
 
1.2.1 Cisplatin and its derivatives 
Interest in using metal complexes as anticancer agents has been 
increasing since the discovery of the antibacterial and anticancer properties of                 
cis-diaminedichloroplatinum(II), cisplatin (Fig. 1.5),[11, 12] which now alone and in 
combination with other drugs, e.g. topoisomerase II inhibitors, antimetabolites 
or mustards, is effectively used in the treatment of several different solid tumors 
such as bladder cancer, small cell lung cancer, head and neck cancers and 
being particularly potent against testicular cancer.[13]  
 
 
Fig. 1.5 Chemical structure of cis-diaminedichloroplatinum(II), cisplatin 
 
 
Although in living cells cisplatin can interact with a number of biomolecules,[14] 
DNA is believed to be its primary cellular target. The mechanism of action of 
cisplatin involves several stages.[15] Once it is administered, it binds to blood 
plasma proteins, mostly to albumin,[16] and is transported in the blood stream.  
Early research suggested that cellular uptake and efflux of cisplatin occurs 
through passive diffusion,[17, 18] however recent studies show that these 
processes can also be linked to copper transport proteins[19, 20] or cation 
transporters.[21] After the compound crosses the cell membrane cisplatin 
undergoes hydrolysis to [Pt(NH3)2Cl(H2O)]+ and [Pt(NH3)2(H2O)2]2+, which then 
Pt
Cl
H3N
H3N
Cl
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can interact with DNA bases forming covalent bonds to N7 positions of purine 
bases, affording primarily formation of 1,2- or 1,3-intrastrand cross-links. This 
results in distortions in the DNA helical structure[22, 23] and its kinking by ~45o 
towards the major groove (Fig. 1.6).[24] The new, induced DNA structure is then 
recognised by cellular proteins such as HMG-domain (High Mobility Group) 
proteins, which have been proposed to inhibit the nucleotide excision repair, 
leading to cell apoptosis.[25]  
 
Fig. 1.6 The crystal structure of duplex DNA containing a cisplatin 1,2-d(GpG) intrastrand    
cross-link (PDB ref. 3LPV)[24] 
 
 
However, the chemotherapeutic application of cisplatin is limited by multiple 
side effects such as neuro-, hepato- or nefrotoxicity,[13] resulting from its lack of 
specificity, and often also by acquired or inherent resistance of tumor cells to 
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this drug.[27, 28] This has led to the development of other alkylating agents, which 
were designed to overcome or, to some extent, diminish the side effects. Five of 
them, carboplatin, oxaliplatin, nedaplatin, lobaplatin and heptaplatin (Fig. 1.7) 
have been approved for clinical use. 
 
 
 
Fig. 1.7 Clinically used platinum-based chemotherapeutics: a) carboplatin, b) oxaliplatin,           
c) nedaplatin, d) lobaplatin, e) heptaplatin 
 
 
 
Carboplatin (Fig. 1.7a) is less antitumor active than cisplatin. This is due to the 
substitution of the chloride ligands with 1,1-cyclobutanedicarboxylate, which 
aquates slowly, thus reduces the reactivity of this compound and consequently 
lowers its cytotoxicity and side effects. Carboplatin is used clinically to treat 
several types of cancer such as ovarian carcinoma, lung, head and neck 
cancer. However, it shows cross-resistance with cisplatin, which indicates the 
same cellular resistance mechanisms to both drugs.[23] Oxaliplatin (Fig. 1.7b) is 
particularly effective against colorectal cancer, where it can also be used in 
combination with 5-fluorouracil, and against cancers that have developed 
resistance towards cisplatin.[29] Nedaplatin (Fig. 1.7c) (approved for clinical use 
in Japan) has been used for treatment of lung carcinoma, head and neck 
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cancers and shows also promising effects in combination therapy.[30] Approved 
in China lobaplatin (Fig. 1.7d) is a mixture of S,S and R,R diastereomers and 
has been approved for treatment of chronic myelogenous leukaemia, metastatic 
breast cancer and small cell lung cancer.[30] 
The above-mentioned platinum drugs fulfil the initially formulated structural 
requirements for metallo-anticancer agents (neutral species with cis- geometry, 
two ammine ligands and two labile ligands that can hydrolyze), however other, 
non-traditional platinum drugs have also been developed.[31] Four of them, 
picoplatin, satraplatin, ProLindac and lipoplatin (Fig. 1.8) are currently in clinical 
trials.[30] 
 
 
 
Fig. 1.8 Platinum-based anticancer drugs currently under clinical evaluation; a) satraplatin,        
b) picoplatin, c) ProLindac 
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1.2.2 Non-platinum antitumor agents 
Platinum based complexes are currently the most successful metallo-
anticancer drugs used clinically for solid tumors,[32] nevertheless using other 
metal ions, with different coordination preferences and physicochemical 
characteristics has been one of the new strategies in the design of new 
generation of anticancer drugs.  This approach has been the subject of many 
investigations in recent years[33, 34] and, among others, complexes of iron,[35] 
gold,[36] titanium,[37] gallium,[38, 39] osmium[40] or ruthenium[41] have been widely 
explored for their anticancer properties.  
 
1.2.3 Ruthenium anticancer drugs 
Ruthenium has a number of properties that may make its compounds 
particularly good alternatives to platinum drugs.[42] These are: octahedral 
coordination geometries, slow ligand exchange kinetics, a range of oxidation 
states reachable in physiological environment (RuII, RuIII, RuIV) and 'the ability to 
mimic iron in the binding to biomolecules’, such as transferrin or albumin.[42] 
Furthermore, the photophysical properties of some ruthenium complexes, 
particularly Ru polypyridyl complexes, can offer many advantages when 
studying the distribution and action of the potential drug in living cells[43] or to 
probe DNA structures.[44] As a result of above there has been an increased 
interest in using ruthenium as a metal center for the design of potential 
anticancer drugs.[41, 45, 46] 
Early investigations of the antitumor properties of Ru complexes demonstrated 
that Ru(III) ammine-based compounds such as cis-[Ru(NH3)4Cl2]Cl and          
fac-[Ru(NH3)3Cl3] show promising antiproliferative effects in leukemia cancer 
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cells.[47, 48] Since then a number of Ru-based complexes have been synthesized 
and tested in vitro and in vivo for their anticancer properties. Three classes of 
such compounds are described below.  
 
NAMI-A, [RuCl4(Im)(S-dmso)](ImH+),[49] and KP-1019, [RuCl4(Ind)2](IndH+)[50] 
(Fig. 1.9) are the Ru-based complexes, which are currently under clinical 
investigations. 
 
 
Fig. 1.9 Ruthenium anticancer drug candidates a) NAMI-A, b) KP1019 
 
NAMI-A, developed by Alessio, has antimetastatic properties and only little 
effect on primary cancers.[51] The exact mechanism of action of this drug is still 
under investigation, nevertheless it is suggested that the antiangiogenic and 
antiinvasive properties of NAMI-A arise from its binding to collagens or to actin-
type proteins.[52-54] 
Developed by Keppler KP1019 exhibits a high level of cytotoxicity in vitro 
against cisplatin resistant colorectal cancer.[49] The activity of this drug is 
believed to be mediated by a mitochondrial pathway.[55] Furthermore, it has 
been shown that KP1019 can bind to iron pockets in transferrin, which has been 
suggested to play a significant role in the mechanism of action of KP1019.[56] 
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Organometallic anticancer complexes have attracted much attention in 
the field of modern medicinal chemistry.[57] Particularly, ruthenium-arene 
complexes with the characteristic ‘piano-stool’ geometry have been extensively 
studied as anticancer drugs.[58-60] Sadler and co-workers developed Ru-based 
complexes of a general formula [Ru(η6-arene)(XY)(Z)]+, where XY is a neutral 
chelating ligand such as ethylenediamine and Z is monoanionic labile ligand 
e.g. Cl- (Fig.1.10a).  
 
 
 
Fig. 1.10 Representative Ru-based complexes tested for anticancer activities: 
a) [(η6-arene)Ru(en)(Cl)]+ , b) RAPTA-C, c) [RuLazpy2Cl2], d) [Ru2La2Cl4] 
 
These compounds possess very promising cytotoxic activities in vitro against a 
range of tumors and are particularly active against ovarian cancer cell lines 
(A2780).[59, 61] The activation of these complexes is believed to take place via 
hydrolysis to [Ru(η6-arene)(XY)(H2O)]2+, and thus it relies on the lability of the 
monoanionic ligand.[62] The aquated species can then interact with 
biomolecules, however it has been proposed that DNA is a cellular target of 
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these compounds.[63] It was shown that they bind to DNA helix with strong 
preference towards N7 of guanine residues.[64] These interactions can be 
assisted by intercalation of the arene moiety between the base stack and also 
by hydrogen bonding of chelating ligand with guanine residues.[65] Moreover, 
studies on structure-activity relationships of these drugs showed that their 
anticancer activity increases with the increased size of the arene ligand (e.g. 
benzene < biphenyl < dihydroanthracene < tetrahydroanthracene),[66] while the 
nature of the chelating ligand does not have a significant influence on the 
cytotoxicity of these compounds.[67]  
Dyson and co-workers have developed another type of Ru-organometallic 
complexes, commonly known as RAPTA compounds (Fig. 1.10b). These are 
based on arene moieties and pta ligands where pta is                                  
1,3,5-triaza-7-phosphatricyclo[3.3.1.1.]decane.[68] Similarly to NAMI-A, RAPTA 
compounds exhibit only little effect on malignant growth, but have been shown 
to selectively target metastases in vivo and display a very low general 
toxicity.[69, 70] Although these compounds can bind to DNA,[71] proteins have 
been proposed to be the biological targets of RAPTA family. It was shown that 
the activity of RAPTA compounds can be mediated by mitochondrial and      
p53-JNK pathways[72] and they act as effective inhibitors of Catepsin B.[73]  
Ruthenium azopyridyl complexes, [RuLazpy2Cl2] where Lazpy is azopyridyl 
ligand (C5H4N)N=N(C6H5) (Fig. 1.10c), are another interesting class of 
ruthenium anticancer drugs. These complexes, due to an asymmetric character 
of the azopyridine ligand, can exist in five different isomeric forms, four of which 
(α-, β-, γ- and δ-) have been structurally characterised.[74] The ruthenium 
azopyridine complexes were found to exhibit cytotoxicity in a wide panel of 
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cancer cells, however it was found that the structural features of these 
compounds remarkably influence their antitumor activities.[75] It was shown that 
the α-[RuLazpy2Cl2] has significantly higher cytototoxicity than the corresponding 
β- or γ- analogues. Moreover, further studies on these systems showed that 
functionalisation of the azopyridine ligand with methyl groups, does not alter the 
general trend in the cytotoxic activity of these compounds.[76] More recently 
Hotze reported a set of isomeric dinuclear analogues of these complexes, 
[Ru2La2Cl4], where La is a bisazopyridine bridging ligand (Fig. 1.10d).[76] Three 
isomers, αα-, αγ-, γγ-, have been isolated and tested in vitro for their 
antiproliferative properties. Interestingly, these compounds showed much 
greater cytotoxic activities than cisplatin and similarly to the mononuclear 
complexes the anticancer properties of the [Ru2La2Cl4] were associated with 
their isomeric differences.[77] However, due to their poor solubility in aqueous 
solution further studies on these systems have not been undertaken. 
The remarkable anticancer effects of Ru-azopyridine complexes might be 
associated with their redox properties.[78] Sadler and co-workers, based on the 
studies on [Ru(η6-arene)LazpyI]+ (Fig.1.11), showed that these complexes can be 
activated by reduction in A549 cancer cells, which results in an increase of the 
level of reactive oxygen species.[79]  
 
 
Fig.1.11 Molecular structure of [Ru(η6-arene)LazpyI]+  
Ru
I
NN
N
R
R = NMe2, OH, H
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Indeed, using azopyridine moiety as a chelating ligand in piano-stool ruthenium 
arene complexes leads also to an increase of inertness of these compounds 
towards hydrolysis. Nevertheless, the studied complexes show remarkable 
effect on human ovarian and lung cancer cell lines (A2780, A549), which may 
imply a different mode of action of these species to that proposed for ‘classical’ 
[Ru(η6-arene)(XY)(Z)]+ compounds.[79]  
 
 
1.3 Supramolecular DNA-binding anticancer drugs 
Over the last few years much attention in modern medicine has been 
focused on the development of novel strategies to target cancer, which could 
potentially allow for the creation of new drugs with unconventional modes of 
action and a new range of cellular activities.[80] Numerous approaches have 
been developed in order to improve bioavailability and specificity of the potential 
drugs and consequently enhance their effectiveness and minimize side effects. 
These innovative strategies include development of drug carriers for improved 
specificity,[81, 82] development of prodrugs that could be, for example, photo-[83] 
or redox activated,[84] but also targeting biomolecules other than DNA i.e. 
proteins or enzymes. Nevertheless, DNA as a ‘blueprint of life’ is still being an 
attractive target for cancer and gene therapy.[85]  
 
While a metal centre in cisplatin and many other related anticancer 
metallo-drugs plays a role as an active centre that binds covalently to DNA and 
induces its structural changes, targeting biomolecules can also be achieved by 
constructing larger, three-dimensional structures, where the metal ion acts as a 
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scaffold for supramolecular frameworks and is not directly involved in the 
interactions with biomolecule.[80] From this aspect supramolecular chemistry 
offers many avenues towards the assembly of ‘small’ molecules that can mimic 
or interfere with biologically important protein or enzyme moieties. As a 
consequence of this such molecules could, much like the natural progenitors, 
selectively target other, larger biomolecules like nucleic acids. This approach, 
followed by rational drug design and comprehensive studies of the 
intermolecular interactions between the drug and its biological target, has a 
great potential for the development of superior alternatives to classical drugs 
not only for gene or cancer therapy but also for wider medicinal applications. 
 
 
1.3.1 Thermodynamics of drug-DNA interactions 
Understanding the molecular insights of drug-DNA interactions can be a 
great facilitator for the sensible design and development of new successful 
therapeutics. Hence, it is important to thoroughly understand the factors 
responsible for drug to biomolecule binding affinity, drug specificity and/or its 
selectivity and have a comprehensive picture of the nature and character of 
drug – DNA complex formation. From this aspect it is essential to fully 
understand the molecular principals of the binding events.  
 
Thermodynamic analysis of the drug-DNA interactions is an important 
accompaniment to structural data. The energetics of the drug – biomolecule 
binding give information about the forces that drive the recognition processes 
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and therefore can be a very useful tool for optimization of current drugs but also 
for the design and development of new therapeutics.  
 
The initial step of the thermodynamic analysis of drug-DNA binding 
involves the determination of the equilibrium binding constant (K) and deriving 
from it binding free energy (ΔG)1. ΔG is a function of enthalpy (ΔH) and entropy 
change (ΔS),2 hence its magnitude depends on a number of factors such as pH, 
ionic strength, temperature, concentration etc.. Although the binding free energy 
is a principal parameter in the thermodynamic analysis, since it is a measure of 
the location of the molecular equilibrium, the thermodynamic analysis of the 
drug-DNA interactions includes determination of binding free energy (ΔG), 
enthalpy (ΔH) and entropy change (ΔS) and heat capacity change (ΔCp). The 
enthalpy change of the binding process can be determined either from the van’t 
Hoff equation based on the relationship between the temperature and 
equilibrium binding constant or using calorimetric methods such as isothermal 
titration calorimetry (ITC) or differential scanning calorimetry (DSC).[86-89] These 
two techniques are the primary methods used for thermodynamic studies of the 
drug-DNA interactions.  
The energetics of drug-DNA recognition (ΔG) is a function of a number of 
events that take place until the system reaches equilibrium. These events, 
among others, include shift of the drug towards the DNA binding site, DNA 
structural changes associated with allocation of the drug, solvation effects as 
well as intermolecular interactions between the drug and the DNA moieties. All 
these events are related to certain energy benefits or penalties. However, if the 
                                                
1 ΔGo = -RTlnK, where ΔGo – Gibbs free energy change, R – gas constant (8.314 J K-1 mol-1), T – temperature (K), K – 
equilibrium binding constant 
2 ΔG = ΔH – TΔS where ΔG – free energy change, ΔH – enthalpy change, T – temperature, ΔS – entropy change 
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recognition is to take place, the magnitude(s) of favorable energetics needs to 
be greater than that of energy costs.[89] 
 
The thermodynamics of the drug-DNA complex formation (ΔG) is 
postulated to be predominantly a function of five Gibbs free energy 
components: ‘conformational changes in the DNA and drug’ (ΔGconf), ‘losses in 
translational and rotational degrees of freedom upon complex formation’ (ΔGr+t), 
‘hydrophobic transfer of the drug from solution to the DNA binding site’ (ΔGhyd), 
‘polyelectrolyte effects’ (ΔGpe) and finally ‘non-covalent interactions between the 
drug and the DNA’ (ΔGmol).[90, 91] 
The binding of the drug to the DNA may induce the DNA structural alterations. 
These include i.e. formation of an intercalation cavity, unwinding and/or 
lengthening of the helix but also its kinking, bending and conformational 
changes. These events cost the system energy and thus have an unfavorable 
contribution to the overall energetics. Early investigations of the 
thermodynamics of the formation of an intercalation pocket for actinomycin D in 
B- and Z-DNA showed that this process is associated with the free energy 
(ΔGconf) of ~ 10 kcal mol-1.[92] More recently, Trieb and co-workers, using 
computational studies on the intercalation of daunomycin and bisdaunomycin, 
showed that the introduction of one single intercalation site in the DNA for 
daunomycin costs the system 32 kcal mol-1, while for double intercalation of 
bisdaunomycin the respective values decreases to 27 kcal mol-1 for the first 
intercalation cavity and 24 kcal mol-1 for the second cavity.[93] These studies 
suggest that binding of one ligand can have an effect on the second binding 
site. 
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The formation of the drug-DNA molecular complex leads to losses in 
translational and rotational degrees of freedom for both DNA and drug. This 
results in an entropic penalty and corresponding adverse free energy 
contribution to overall energetics of the molecular complex formation (ΔGr+t > 0).  
The hydrophobic transfer of the drug to the DNA binding site is an energetically 
favorable process and consists of two components: enthalpic contribution 
arising from the stabilization of water molecules released from the DNA    
binding site by interaction with these from the bulk solvent, and entropic 
contribution, which is associated with disruptions of the solvent structure.[94, 95] 
An approximate magnitude of the energetics corresponding to the hydrophobic 
transfer (ΔGhyd) of the drug to DNA can be determined from changes in solvent 
accessible surface areas (ΔSASA) or from heat capacity changes (ΔCp).[96, 97] 
The free energy corresponding to the hydrophobic shift of the binding molecule 
to the DNA binding site seems to have a major favorable contribution to the 
energetics of the drug-DNA binding event.[90] 
Since DNA is a highly charged polyanion, in the buffer the counterions (e.g. 
Na+) are condensed around the biomolecule.[98, 99] The recognition by the 
positively charged drug results in a release of these counterions (polyelectrolyte 
effect) and this gives a substantial favorable entropic contribution to the binding 
free energy. Consequently, the magnitude of ΔGpe depends on the ionic 
strength of the buffer and also on the charge of the binding molecule.3  
The intermolecular interactions between the host molecule and the binding drug 
also contribute to the thermodynamic profile of the binding process. Hydrogen 
bonding, van der Waals interactions etc. result in favorable enthalpy 
                                                
3 δ lnK / δ lnM+ = -Zφ, where: K- ligand binding constant, M+ - monovalent cation concentration, Z – charge on the 
ligand, φ - fraction of monovalent cation associated per DNA phosphate, φB-DNA = 0.88  
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contributions,[100] however assignment of the energetic contributions to the 
constituent non-covalent interactions is not trivial and requires consideration of 
a number of factors.[101] 
As described above, the energetics of drug-DNA binding is a function of several 
thermodynamic components, which can have an additive and cooperative 
contribution to the overall free energy of the recognition process. For example, 
hydrophobic shift of the drug towards the DNA binding site can result in 
variations in the DNA hydration, which in turn can induce substantial distortions 
in DNA structures like conformational changes or helix unwinding.[102] All these 
effects are associated with certain energy gains and losses, some of which can 
balance or compensate each other thus determining the affinity of drug to 
biomolecule. 
 
1.3.2 Metallointercalators and metalloinsertors 
Intercalators are poly(hetero)cyclic aromatic compounds often with a 
large planar surface that bind reversibly to DNA by inserting their extended 
ligands in between the stacked base pairs and forming with them face-face π-π 
interactions. The intercalation ordinarily results in local alterations in the DNA 
structure, which may include helix lengthening and/or unwinding. Intercalators 
can be considered to be the largest and most investigated group of non-
covalent DNA binders with anticancer activity.[103-105] Many organic intercalators 
such as acridine or anthracene derivatives have been widely explored for their 
antitumor properties and some of them, such as doxorubicin or daunorubicin  
(Fig. 1.12), are already in clinical use for chemotherapeutic treatment of 
different cancers.  
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Fig. 1.12 Clinically used DNA intercalating anticancer drugs; (left) doxorubicin, (right) 
daunorubicin 
 
 
However, metallo-intercalators represent a different category of DNA-binding 
antitumor agents. The introduction of metal centers gives, in addition to the 
potential for hydrophobic effects and π-π interactions, an electronic contribution 
to the overall binding efficiency of a drug. Furthermore, the binding 
characteristics and therefore biological effects of the metallointercalators may 
be fine tuned through judicious selections of the ancillary ligands.  
 
The first metallointercalator, [Pt(terpy)(SCH2CH2OH)]+ reported by Lippard and     
co-workers consisted of a terpyridine unit bound to Pt center (Fig. 1.13) and 
was shown to reversibly bind to polymeric DNA, which results in the DNA 
lengthening.[106, 107]  
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Fig. 1.13 Molecular structure of [Pt(terpy)(SCH2CH2OH)]+ 
 
 
A number of other square-planar complexes with different extended aromatic 
moieties such as terpyridine, phenanthroline, bipyridyne or DPPZ have been 
investigated for their intercalative properties and, in addition to their DNA 
binding characteristics, the structure-activity relationships  (SAR) of such 
complexes have also been investigated. For example, based on the studies on 
platinum methyl-substituted phenanthroline systems, Aldrich-Wright showed 
that the cytotoxic activities of these complexes depend not only on the amount 
of methyl groups and their location in the phenantroline moiety but also on the 
character and configuration of the ancillary ligands.[108-111] 
 
Octahedral metal-based metallointercalators, mainly of Ru(II) and Rh(III), have 
been extensively studied by Barton and co-workers.[112] An example of such a 
complex is Δ-[Rh(phi)(R,R-Me2trien)]3+ (phi - 9,10-phenanthrenequinone diimine 
and  R,R-Me2trien - 2R,9R-2,9-diamino-4,7-diazadecane)  (Fig. 1.14), which 
stereospecifically recognizes 5’-TGCA-3’ DNA sequences.[113]  
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Fig. 1.14 Molecular structure of [Rh(phi)(Me2trien)]3+  
 
The crystal structure of Δ-[Rh(phi)(R,R-Me2trien)]3+ bound to DNA 
oligonucleotide, 5'-G-dIU-TGCAAC-3', shows that the compound targets DNA 
duplex from the major groove, where the aromatic moiety of the complex 
intercalates deeply between GC base stacks, whilst the ancillary ammine 
ligands form hydrogen bonds with the guanine edges (Fig. 1.15).[114]  
 
 
Fig. 1.15 Intercalation of [Rh(phi)(Me2trien)]3+ (PDB ref. 454D) [114] 
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Important examples of metal complexes that bind stereoselectively to DNA are 
Δ-[Rh(bpy)2chrysi]3+, and Δ-[Rh(bpy)2phzi]3+, where bpy - 2,2’-bipyridine,       
chrysi - chrysene-5,6-dione, phzi - benzo[a]-phenazine-5,6-quinone diimine              
(Fig. 1.16). 
 
 
 
Fig. 1.16 Mismatch specific metallo-insertors: (left) Δ-[Rh(bpy)2chrysi]3+, (right)                          
Δ-[Rh(bpy)2phzi]3+. 
 
These two complexes, due to the extended aromatic surfaces of their diimine 
moieties, chrysi and phzi, do not intercalate into the ordinary DNA duplex, but 
instead show a high specificity towards mismatched DNA structures. NMR 
solution studies with a CC mismatched DNA sequence and further X-ray 
analysis of the complex Δ-[Rh(bpy)2(chrysi)]3+ with the AA mismatched 
oligonucleotide duplex, 5’-CGGAAATTACCG-3’, reveal that the complex 
recognizes DNA from its minor groove side.[115, 116] It subsequently inserts its 
chrysi ligand between the base pairs, ‘ejecting the mismatched nucleobase into 
the major groove’, and interacts with DNA bases via π-π stacking. Interestingly, 
upon photoactivation, these complexes induce the DNA strand breaks in the 
position opposite to the mismatch site[117, 118] and furthermore exhibit 
antiproliferative properties in cancer cells.[119] These effects were shown to be 
associated with the chiral nature of the binding complexes and thus their ability 
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to recognize the DNA mismatches.[119] The Δ-enantiomers of [Rh(bpy)2 chrysi]3+ 
and [Rh(bpy)2phzi]3+, which can bind to DNA mismatched sequences were 
found to exhibit antiproliferative properties in cancer cells, while the Λ-isomers 
did not display such features. Studies on the chrysi family of compounds, 
[RhL2chrysi]3+, where L is NH3, DIP, HDPA, 2,2’-bipyridine and                      
1,10-phenanthroline, confirm the correlation between the DNA mismatch 
recognition and the antiproliferative activity of these compounds.[120] Moreover, 
these studies also demonstrate that the ancillary ligands can alter the mismatch 
binding affinity of the rhodium metalloinsertors.  
 
Bisintercalators are another interesting class of non-covalently DNA-binding 
drugs. They consist of two linked intercalating moieties, however the DNA 
binding properties of such molecules depend predominantly on the character of 
the linking ligand.  
Interesting DNA binding properties are shown by bisintercalators based on 
hairpin-shaped platinum motifs linked via lanthanide moiety (Fig. 1.17). These 
complexes can act as luminescent probes for DNA structures,[121] but also, as 
shown by Crossley, can selectively target tumor cells, accumulating particularly 
in cell nuclei.[122]  
 
Fig. 1.17 Gadolinium bisintercalator; Figure adapted from ref. [122] 
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Lowe and co-workers developed a series of potential DNA bisintercalators with 
substituted terpyridine ligands linked via rigid spacer groups.[123] Studies on the 
cytotoxic activities in glioma cell lines showed that these systems exhibit 
promising anticancer activities, but they were also shown to inhibit human 
thioredoxin reductase.[124]  
 
Bisintercalators studied by Lincoln are structurally different from these 
described above. Here the two metallointercalators e.g. [Ru(phen)2dppz]2+ are 
linked via dppz moiety (Fig. 1.18), hence classical intercalation can not 
occur.[125] These compounds present unusual DNA binding modes, in which the 
bridging ligand is inserted between base pairs with the two Ru centers located 
in opposite DNA grooves i.e. threading effect. 
 
 
Fig. 1.18 The threading bis-intercalator [µ(bidppz)(phen)4Ru2]4+. 
 
Studies on the effect of the bridging ligand on the threading properties of this 
kind of compound showed that their threading efficiency is determined by length 
and flexibility or rigidity of the bridging ligand.[126] Nevertheless, these 
complexes, particularly [µ(bidppz)(phen)4Ru2]4+, have been found to selectively 
target alternating AT base pairs.[127] 
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1.3.3 Binding to sugar-phosphate backbone 
Polynuclear metal complexes can be a promising alternative to the 
mononuclear supramolecular DNA-binding metallo-drugs.[128]  
TriplatinNC and TriplatinNC-A (Fig. 1.19), the non-covalent DNA-binding 
analogues of the clinically investigated BBR3464, within DNA interact 
exclusively with the DNA phosphate backbone.[129]   
 
 
 
 
Fig. 1.19 The chemical structures of trinuclear phosphate clamps:  a) TriplatinNC-A,                  
b) TriplatinNC 
 
 
The crystal structure of TriplatinNC with the Dickerson-Drew Dodecamer        
(5’-CGCGAATTCGCG-3’) shows the selective interactions of the platinum 
complex with oxygen-rich polyanionic sugar-phosphate backbone                  
(Fig. 1.20).[129] This recognition takes place mainly through electrostatic 
interactions and formation of amine(NH)···phosphate(O)···ammine(HN) 
hydrogen bonds with the phosphate oxygens.  
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Fig.  1.20 Recognition of phosphate backbone by trinuclear platinum complex (left) side view, 
(middle) top view (right) spanning of two phosphate backbones, (PDB ref. 2DYW).[129] 
 
 
In vitro testing of TriplatinNC and TriplatinNC-A for their anticancer properties 
shows that both complexes, exhibit micromolar cytotoxicity against certain 
ovarian cancer cell lines.[130] However, the TriplatinNC seems to be remarkably 
more active than TriplatinNC-A. This was suggested to be attributed to the 
cellular uptake of both compounds. 
 
 
1.3.4 Beyond the canonical right-handed double helix 
The research on DNA binding drugs for a long time was focused on the 
recognition of B-DNA structures. However, over the past few years much 
attention has been drawn to targeting non-classical structures and 
conformations of nucleic acids such as branched DNA structures, DNA hairpins, 
triplexes or quadruplex DNA topologies. 
 
 
 29 
1.3.4.1 DNA junction structures recognition 
Hannon and co-workers developed a series of metallo-supramolecular 
dinuclear triple-stranded helicates, which have a size and shape similar to helix-
turn-helix protein DNA recognition units (~2 nm in length and ~1 nm in 
diameter). These compounds were found to bind strongly to the major groove of 
the DNA, promoting bending and intramolecular DNA coiling,[131] but were also 
shown to target the core cavity of DNA Y-shaped junctions without causing 
alterations in the DNA structure (Fig. 1.21).[132-135] 
 
 
Fig.1.21 Recognition of DNA three way junction by metallo-supramolecular helicate.                 
Left (top view), right (side view) (PDB ref. 2ET0).[132] 
 
 
The crystal structure of the Fe helicate with the palindromic DNA sequence    
(5’-CGTACG-3’) showed the complex DNA-helicate to be stabilized by a 
number of supramolecular interactions: π-π stacking between base pairs and 
phenyl rings of the cylinder (Fig. 1.22), CH…N hydrogen bonding, hydrophobic 
effects, as well as sandwiching interactions on the minor groove side.[132]  
However, this kind of recognition is not limited to the palindromic DNA 
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sequences, yet the cylinders can recognize different DNA three-way junction 
topologies.[136]  
 
Fig. 1.22 The stacking of the DNA bases with the phenyl rings of one strand of the triple-helicate 
(PDB ref. 2ET0).[132] 
 
 
In vitro supramolecular helicates exhibit cytotoxicity only 2-5 fold lower than 
cisplatin,[137] but unlike the latter drug they were found to be non-genotoxic.[138] 
They cause arrest of the Go/G1 phase of cell cycle[138] and were also found to 
inhibit DNA transactions by interfering with Taq polymerase binding to DNA.[139] 
This can be a strong indication that the non-covalent DNA binding 
supramolecular cylinders may be able to influence the processing of the genetic 
code by proteins. 
 
1.3.4.2 G-quadruplex DNA recognition 
Quadruplex nucleic acids are four-stranded DNA structures based on 
hydrogen-bonded guanine quartets (Fig. 1.23).[140, 141] They are found in e.g. 
chromosomal DNA, especially in telomeres, ribosomal DNA and in the 
promoters of genes. The formation of quadruplex structures inhibits the 
telomerase enzyme from maintaining telomere length,[142] which prevents the 
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cell senescence and further apoptosis.[143] Therefore, molecules that selectively 
target or induce formation of quadruplex DNA can be a new class of anticancer 
drugs.[144, 145]  
 
 
 
Fig. 1.23 Structure of G-quadruplex (PDB ref. 1KF1)[141] 
 
 
The general properties of G-quadruplex DNA recognizing agents include 
cationic charge and an extended, planar aromatic core suited for π-π stacking 
with the G4 ‘surface’. Numerous metal-based compounds have been shown to 
selectively recognize G-rich DNA sequences.[146] For example, piperidine 
functionalised, square-planar nickel(II) complex (Fig. 1.24a) was found to be 
>50 fold more effective in stabilizing G-quadruplex structures over duplex DNA, 
and was shown to inhibit telomerase activity at concentrations of 0.1 µM.[147] 
More recently, it was reported that a terpyridine-based bimetallic complex binds 
even more strongly to quadruplex DNA with around 100 fold better selectivity 
towards these structures versus duplex DNA.[148] It has been proposed that the 
binding properties of this dinuclear compound arise from its dual mode of 
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action, which involves π-π stacking of the terpyridine unit with G-quartets and 
the interaction of the metal-dipicolyl moiety with the DNA backbone.  
 
 
 
Fig. 1.24 Chemical structures of G-quadruplex recognizing agents; a) Nickel-salphen complex, 
b) Manganese porphyrin complex. 
 
 
The functionalisation of the terminal regions of the planar moiety with flexible 
‘arms’ appears to be a favoured strategy for improving the selectivity of the      
G-quadruplex binding agents. One of the leading examples of this type of drug 
is a manganese-porphyrin complex (Fig. 1.24b), consisting of a flat aromatic 
core and four flexible arms suited to non-covalent interactions with the grooves 
and loops of the G-quadruplex structures. This compound was found to be        
>10 000 times more selective towards G-quadruplex sequences compared to 
duplex DNA.[149] Nevertheless, the high cationic charge of this complex also 
makes a substantial contribution to the energetics and stabilization of the 
system. Guanidiniozinc phtalocyanines (Fig. 1.25), reported by Luedtke[150] are 
further intriguing compounds of this genre.  
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Fig. 1.25 Molecular structure of guanidiniozinc phtalocyanines 
 
Zn-DIGP (shown in Fig. 1.25, where R = iPr), not only extremely strongly and 
selectively binds to the c-myc DNA, but also exhibits ‘turn-on’ luminescence 
upon binding to this structure.[150] Interestingly, this complex was shown to be 
able to reduce mRNA expression.  
 
 
Breaking old, cisplatin rules and finding novel strategies for the 
development of new drugs can be a crucial step to obtain new selective and 
targeted drugs with novel mechanisms of action and a wide range of cellular 
activities. Supramolecular chemistry can have a great input into this new 
approach. Creating new drugs, where the metal ion can act as a scaffold for the 
assembly of three-dimensional structures for the selective recognition of the 
biologically important molecules, can draw a line between traditional metallo-
drugs and future therapeutics.  
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1.4 Aim and outline of this thesis  
In this work the supramolecular approach is used for the design and 
preparation of new kinetically stable dinuclear cylinder-shaped metal complexes 
that can interact with biomolecules exclusively via non-covalent interactions.  
 
The aim of the research described in this work is to synthesize new derivatives 
of the rare, stable, fluorescent ruthenium triple-stranded helicates and to 
investigate the factors that influence their biomolecule binding properties and 
biological activities. The second objective is to understand the effect of chirality 
on the DNA binding properties of the above systems. 
Chapter 2 addresses the improved methodologies applied to the synthesis and 
purification of ruthenium(II) triple stranded helicates with imine-based ligands as 
well as the synthesis and characterisation of three new Ru cylinders.  The new 
compounds were studied for their DNA binding properties. All complexes were 
found to interact with ct-DNA and coil/bend DNA. Complexes also extensively 
unwind negatively supercoiled DNA and possess promising micromolar 
cytotoxicities against human breast cancer cell lines.  
Chapter 3 presents the enantiomeric resolution of left and right-handed Ru 
triple-helicate and DNA binding studies of these enantiopure isomers using a 
number of spectroscopic techniques. Both enantiomers were found to have 
different DNA binding properties but were individually similar to their previously 
reported Fe analogues.  
In Chapter 4 the interaction of racemic mixture and enantiopure optical isomers 
of the Ru(II) cylinder with a chiral shift reagent  (Δ-TRISPHAT) is investigated 
using   1H NMR spectroscopy.  
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Chapter 5 describes the synthesis and characterisation of ammine and 
azopyridyl based mono and dinuclear Ru(II) complexes. DNA binding studies of 
these compounds using a number of spectroscopic techniques are also 
presented.  
In Chapter 6 detailed experimental synthetic procedures and characterisation of 
new compounds are presented. The details of the biological studies are also 
provided. 
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2 
Dinuclear Ru(II) Triple-Stranded Helicates 
Synthesis, DNA Binding and Cytotoxic 
Activities 
 
 
 
Abstract 
In this chapter improved methodologies for the synthesis and purification of rare Ru(II) triple-
stranded helicates with different structural topologies are described. Three new ruthenium 
cylinders have been synthesized and characterised and the molecular structures of 
[Ru2Lo3](PF6)4 and [Ru2L2-im3](PF6)4 where Lo is  an oxygen bridged bispyridylimine ligand 
(C6H4N)C=N(C6H5)O(C6H5)N=C(C6H4N) and L2-im is 2-substituted bisimidazoleimine ligand 
(C3H4N2)C=N(C6H5)CH2(C6H5)N=C(C3H4N2)  have been determined by X-ray diffraction 
analysis. The DNA binding of all three new complexes has been investigated using UV-Vis, 
circular and linear dichroism spectroscopy and an agarose gel electrophoretic mobility shift 
assay. The compounds have also been investigated for their cytotoxic activities against human 
ovarian cancer cell lines.  
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2.1 Introduction to supramolecular cylinders 
In nature, sequence-specific DNA recognition relies primarily upon the 
formation of hydrogen bonds between DNA nucleobases and protein subunits 
e.g. helix-turn-helix, zinc fingers, or alternatively on ‘indirect readout’, which 
principally involves the sequence-dependent structural deformability of the DNA 
helix. This discrete DNA recognition is a distinctive feature of cellular regulatory 
processes such as regulation of gene expression. Indeed, uncontrolled cellular 
reproduction events i.e. DNA transactions such as replication or transcription 
may result in diseased conditions, which then may lead to cancer or viral 
infections. Developing small molecules that can selectively and specifically 
interact with nucleic acid structures or sequences has been of great interest in 
modern medicinal chemistry. Such molecules could restrict or moderately affect 
processing of genetic code and thereby act to regulate cellular processes. From 
this aspect there has been much effort devoted to creating synthetic molecules 
that could interact with DNA in a protein-like fashion.[1] 
 
Research in Hannon group led to the development of metallo-
supramolecular assemblies, which have a size and shape similar to natural 
protein DNA recognition subunits (Fig. 2.1).[2] 
 
 
Fig. 2.1 Structure of the iron triple-stranded helicate, [Fe2L3]4+ 
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These compounds are cationic, dinuclear triple-stranded helicates built of three 
bisbidentate ligands wrapped around two metal centers in a helical fashion. The 
cylinders were found to recognize the major groove of the DNA spanning five 
base pairs and causing substantial intramolecular coiling of polymeric DNA.[3, 4] 
It was also found that the specific dimensions of metallo-supramolecular 
cylinders (2 nm in length and 1 nm in diameter) are crucial for their distinctive 
DNA binding properties.[5, 6] More recently, an iron helicate was shown to target 
the core cavity of DNA three-way junctions (Fig. 2.2) without causing alterations 
in the DNA structure.[7-9] 
 
 
Fig. 2.2 Crystal structure of an iron(II) triple-helicate bound to the junction point of a DNA    
three-way junction (PDB ref. 2ETO).[7] 
 
 
 
 
Gel electrophoresis studies showed that a cylinder can recognize a variety of 
different Y-shaped junction topologies.[10] In fact DNA three-way junction 
structures are present during DNA replication and these structures have also 
been found to be involved in several human diseases such as Huntington’s 
disease.[11] Therefore, this new mode of DNA recognition opens up the 
opportunity to approach new biological targets and can also be a very powerful 
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tool in studies of DNA replication or transcription processes, for instance by 
interfering with or monitoring them. 
The biological studies show that the iron(II) cylinder binds to the bacterial DNA 
and exhibits antimicrobial properties against B. subtilis and E. coli.[12] Further 
biological evaluation of metallo-supramolecular helicates showed that the 
cylinders exhibit antiproliferative properties in a wide range of human cancer 
cell lines without causing genotoxic or mutagenic effects.[13] It was also found 
that the level of cytotoxicity of supramolecular cylinders depends on both the 
incubation time and the total amount of drug applied.[14] 
 
Several different helical systems have been developed to study their 
effects on DNA structures. These include copper helicates, which were shown 
to be able to act as synthetic nucleases[15] and a ruthenium triple-stranded 
helicate, which has similar structural characteristics to its previously 
synthesized iron(II) analogue (Fig. 2.3).[16, 17] 
 
 
 
 
Fig. 2.3 Overlay of crystal structures of ruthenium (II) triple-stranded helicate (red) and its iron 
(II) analogue (yellow); Figure taken from [17]. 
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Although the DNA binding and coiling properties of the ruthenium cylinder were 
found to be comparable to these of iron cylinder, unlike the latter complex, this 
compound causes DNA strand breaks upon irradiation with UV-Vis light thus 
cleaving DNA in a sequence-dependent fashion, mostly at guanine bases.[18] 
There were also found to be some differences in the cytotoxic activities of the 
ruthenium and iron helicates. While iron cylinder exhibits micromolar cytotoxicity 
in breast and ovarian cancer cell lines, ruthenium analogue was found to be 
active only in breast cancer cells (T47D and HBL100).[16] 
  
The above-mentioned biological effects of the cylinders were believed to be a 
consequence of their binding to the DNA. However, further studies on these 
complex-DNA systems had to be undertaken in order to access more detailed 
information on the mechanism of action and to better understand the possible 
relationship between their DNA binding properties and cellular effects.    
 
Although in the Hannon group DNA binding studies focused primarily on 
Fe(II) supramolecular cylinders, the lack of stabilities of these systems in 
aqueous solution limited the scope of experiments that could be performed. 
Since the ruthenium analogue proved to be very stable in aqueous solution and 
biological mediums,[17] and the structural properties of the cylinders were 
believed to be crucial for cylinder-like activities, the [Ru2L3]4+ was chosen as an 
alternative model compound for our systems. The fluorescent properties of this 
compound are also useful for probing DNA binding and, most importantly, 
investigating and monitoring of the action of the drug in living cells.  
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Formation of dinuclear triple-stranded helicates is ordinarily a 
spontaneous self-assembly process. An example of this can be the preparation 
of an iron cylinder, where the pure compound can be obtained within 2 hours in 
a high yield.[2] However, using inert metal ions, such as Ru(II), as building units 
for the helicate may disrupt or hinder the assembly of such systems. Indeed the 
synthesis and purification of the ruthenium analogue of the iron triple-stranded 
helicate initially proved to be very challenging, giving an analytically pure 
compound in ~ 1 % yield.[16] Thus, having established that the ruthenium 
compound can be a valuable probe for our systems the first aim of the work 
presented in this chapter was to find new, improved strategies towards 
synthesis and/or purification of the Ru-based triple-stranded helicates, which 
would allow further, detailed biological studies on these systems. 
 
2.2 Results and discussion 
2.2.1 Synthesis of [Ru2L3]Cl4  
A few reports on the formation of the heterometallic helicates containing Ru(II) 
are found in the literature.[19-22] However, as yet there are only two literature 
examples of the homometallic ruthenium triple-stranded complexes.[16, 23] 
Synthesis of the very first Ru(II) triple-stranded cylinder with bispyridylimine 
ligands was reported in 2007 by Pascu.[16] Later, in 2008, Glasson and           
co-workers showed that microwave irradiation could also be employed for the 
successful synthesis of this class of Ru compounds.[23] Using quaterpyridine 
ligands as building blocks for the cylinder and the microwave radiation based 
synthetic methodology allowed to obtain an analytically pure product in 36 % 
yield. 
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To initiate the project on ruthenium triple-stranded helicates it was first decided 
to repeat the original synthesis of Pascu, but to explore other ways of 
purification. Following this, alternative methods of synthesis were also explored. 
 
Ligand L (Fig. 2.4) was synthesized following a previously published method.[2] 
 
 
Fig. 2.4 Molecular structure of L 
 
The synthesis of [Ru2L3]Cl4 was performed by reacting cis-[Ru(DMSO)4Cl2] and 
ligand L under argon atmosphere for 7 days. This was followed by silica gel 
column chromatography to obtain a pure material in a final yield of 11 %. The 
1H NMR spectrum of the purified compound is shown in Fig. 2.5. 
 
 
Fig. 2.5 1H NMR spectrum of [Ru2L3](PF6)4 in CD3CN 
 
The mass spectrum of the chloride form of the compound reveals peaks 
corresponding to [Ru2L3]4+ (m/z 333.1), [Ru2L3]3+ (m/z 444.0), [Ru2L3]Cl2+      
N N
N N
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(m/z 683.7) and [Ru2L3]Cl22+ (m/z 701.2) and analytical purity of the obtained 
compound was confirmed by elemental analyses.   
 
The purification of the Ru triple-stranded helicate on the silica gel seems to be 
more efficient than the original purification technique on an alumina column 
(neutral alumina with CH3CN/H2O/sat. KNO3, 20:1:1) where, during the 
purification process, a part of the compound remains on the column and this 
subsequently lowers the final yield. Although the multiple columning necessary 
for the purification using the silica gel also leads to the loss of some of the 
product, the amount lost is less than using the alumina. However, to try to 
minimize the loss of the compound at this stage alternative purification routes 
were pursued.  
A superior technique for purification of ruthenium triple-stranded helicate was 
found to be positive ion exchange chromatography on Sephadex C-50 resin 
with a gradient of aq. NaCl (0.05 – 0.8 M). This involved using the water-soluble 
chloride salt of the crude. Nevertheless, using this method an analytically pure 
compound was obtained in 16 % yield, which was improved by a factor of 60 
over the original yield reported by Pascu.  
This method was found to be moderately more efficient in terms of yield than 
the silica gel approach, and unlike the previously discussed technique it does 
not necessitate multiple columning, which shortens the total required time for 
the purification and avoids the possibility of losing part of the product on the 
next column or in the analyses of the multi-step purification process.  However, 
alternative avenues towards the synthesis of [Ru2L3]Cl4 were also investigated.  
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Following Glasson strategy, it was found that ruthenium bispyridylimine ligand-
based cylinder could also be effectively obtained using microwave irradiation. 
Exposing the mixture of cis-[Ru(DMSO)4Cl2] and ligand L in ethylene glycol to 
microwave energy for 4 sequential 1h long cycles at 180oC, followed by silica 
gel or cation exchange chromatography, gives the desired product in yield of 
12-18 %. This is comparable to the yield obtained in the reflux-based 
methodology. 
One of the important factors in the formation of the desired compound 
appears to be the need for a rapid increase in the energy for the reaction 
mixture.  Due to the ease of formation of a number of kinetic by-products it is 
necessary to drive the reaction towards the desired, thermodynamically 
controlled, metallo-assemblies. That factor notwithstanding, the formation of the 
presumed polymeric impurities still appears to be unavoidable in these systems.  
 
Although all the above-described strategies for the synthesis and 
purification of ruthenium triple-stranded helicate give similar yields, considering 
the overall timescale of the reaction and the purification efficiency, it can be 
concluded that the most satisfactory results were obtained when using the 
microwave reaction approach combined with purification by cation exchange 
chromatography. In summary, both, reaction yield and time requirements were 
substantially improved compared to the previously reported results.  
These results demonstrated the viability of making ruthenium triple-helicates 
and allowed for the greatly expanded research and utility of this family of 
compounds in DNA-binding studies and in cells. 
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2.2.2 Towards a library of ruthenium triple-stranded helicates 
It was found that the Ru cylinder, similarly to its iron analogue, can 
recognize and stabilize DNA and RNA three way-junction structures.[24] Further 
in vitro studies of the action of the Ru cylinder on the DNA showed that this 
compound ‘can affect the ability of proteins to process the DNA code’ by 
affecting Tag polymerase binding to ds-DNA.[25] Explicit research on the action 
of the Ru compound in living cells has also been undertaken.[26] For instance, 
studies on the cellular uptake and distribution of the Ru cylinder using ICP-MS 
showed that the compound can cross the cell membrane and reach the  
nucleus within a relatively short time (3h). It was found that only 3 hours after 
treatment already 60% of the total uptaken cylinder was accumulated in the cell 
nucleus.[26] These findings were further confirmed by confocal microscopy. 
These and previous interesting results obtained for the ruthenium parent 
cylinder led to the initiation of a project for developing other, kinetically stable, 
fluorescent Ru cylinders. This entitled creating a library of Ru cylinders and 
screening them for their biomolecule binding properties and their action in cells 
with an ultimate goal to investigate the structure – function or structure - 
cytotoxicity relationship in these systems. From this aspect three other Ru 
triple- stranded cylinders have been prepared.  
 
 
2.2.3 Synthesis and characterisation of [Ru2Lo3]Cl4 
Ligand Lo (Fig. 2.6) is analogous to the ligand L but the -CH2- group in 
the centre of the ligand has been replaced by an oxygen atom. The ligand Lo 
was prepared by reacting two equivalents of 2-pyridine carboxaldehyde with 
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one equivalent of 4,4’-diaminodiphenyl ether in methanol.[27] The 
characterisation of this compound was in agreement with the literature data. 
 
Fig. 2.6 Molecular structure of Lo 
 
The newly developed synthetic and purification procedure for the parent 
[Ru2L3]Cl4 was proved to be successful also for the new pyridine system with 
oxygen bridged ligand Lo. [Ru2Lo3]Cl4 was synthesized by reacting the two 
equivalents of cis-[Ru(DMSO)4Cl2] with three equivalents of ligand LO in 
ethylene glycol at 200oC for 7 days. Analogously to the previously described 
method, successful purification was performed on the silica gel column with 
aqueous 5-15 mM NH4PF6/CH3CN as an eluent. This was followed by anion 
metathesis with t-Bu4NCl yielding the pure compound in a 8 % yield. The         
1H NMR spectrum reveals one set of aromatic proton resonances (Fig. 2.7), 
confirming the high symmetry of the isolated compound.  
 
Fig. 2.7 1H NMR spectrum of [Ru2Lo3]Cl4 in MeOD. 
O
N N
N N
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The electrospray mass spectrum (of the chloride salt of the compound) shows 
peaks with the isotopic distribution corresponding to [Ru2Lo3]4+ (m/z 334.6) and 
[Ru2Lo3]Cl3+ (m/z 457.5) cations. Elemental analysis data were consistent with 
[Ru2Lo3]Cl4 formulation. Dark orange crystals suitable for X-ray analysis were 
obtained by slow diffusion of diethyl ether into an acetonitrile solution of the 
hexafluorophosphate salt of the compound at 4oC. The compound crystallized 
in an orthorhombic crystal system with the space group Pbca. The crystal 
structure confirms the formation of the dinuclear cation with three bis-bidentate 
ligands wrapped around two metal centers in a helical fashion. The Ru-N 
distances are in the range of 2.03 – 2.11 Å and the Ru centers are separated by 
11.3 Å (Fig. 2.8). 
 
 
Fig. 2.8 Crystal structure of cation in [Ru2Lo3](PF6)4. Hydrogen atoms, counterions and solvent 
molecules are omitted for clarity, red-O, blue-N, grey-C, orange-Ru 
 
 
 
This structure is highly similar to the structure of the corresponding Ru(II) 
cylinder with ligand L reported by G. Pascu (Fig. 2.9) and further, to the Fe(II) 
analogue of the latter complex.  
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Fig. 2.9 Overlay of structures of cations in [Ru2L3](PF6)4 (grey) and [Ru2Lo3](PF6)4 (red) 
 
The deep orange colour of the complex is typical for RuN6 chromophores.[16] The 
UV-Vis spectrum shows the MLCT band with the maximum at 485 nm                       
(ε = 21 500 M-1 cm-1 in H2O) and inter-ligand transition bands centered at 322 
and 270 nm (Fig. 2.10). Similarly to the ruthenium parent cylinder, as it has the 
same coordination sphere, the compound is fluorescent and excitation in the 
MLCT region (λex = 485 nm) gives rise to the emission band centered at 705 nm     
(Fig. 2.10). 
 
 
Fig. 2.10 Absorption (black) and emission (red) spectra of [Ru2Lo3]Cl4 recorded in water              
(λex = 485 nm). Spectra are not on the same scale. 
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2.2.4 Synthesis and characterisation of [Ru2L2-im3]Cl4 
To investigate whether changing the coordination sphere of ruthenium, 
while maintaining the spacer group, can influence the DNA binding properties of 
the cylinder, helicates with modified ligand structure at the metal binding unit 
were explored. 
Ligand L2-im (Fig. 2.11) was prepared from commercially available                 
4,4’-methylenediamine and 2-imidazolecarboxaldehyde following the synthetic 
procedure detailed by M. Pascu.[28] 
 
 
Fig. 2.11 Molecular structure of L2-im 
 
The coordination of the ligand to the ruthenium center was performed by 
method analogous to that for pyridine complexes, by stirring under reflux two 
equivalents of cis-[Ru(DMSO)4Cl2] and three equivalents of ligand L2-im in 
ethylene glycol at high temperature (200oC) for 6 to 7 days. Initial purification 
was performed simply by extraction of the compound from the crude product 
using ethanol. This was further followed by silica gel column chromatography 
and anion metathesis to obtain the analytically pure [Ru2L2-im3]Cl4 in 1 % yield.  
The 1H NMR spectrum shows a single set of peaks, which indicates that a 
single, symmetrical species have been isolated (Fig. 2.12). The mass spectrum 
shows two peaks with the isotopic distribution corresponding to dinuclear Ru(II) 
complex, a peak at 632.5 m/z, [Ru2L2-im3]2+ and peak at 316.5 m/z, which 
corresponds to [Ru2L2-im3]4+. 
N N
H
N
N N
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N
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Fig. 2.12 The aromatic region of the 1H NMR spectrum of [Ru2L2-im3]Cl4 in MeOD. 
 
Orange crystals suitable for X-ray analysis were obtained by slow diffusion of 
diethyl ether into an acetonitrile solution of the compound at 4oC. The 
compound crystallized in the monoclinic crystal system with the space group 
C2/c. The crystal structure shows the complex to be dinuclear with two metal 
centers linked by three ligands in a helical arrangement (Fig. 2.13).  
 
 
 
Fig. 2.13 Crystal structure of cation in [Ru2L3](PF6)4. Hydrogen atoms, solvent molecules and 
counter ions are omitted for clarity, blue-N, grey-C, orange – Ru. 
 
 
The two metal centers are separated by 11.4 Å, and the Ru-N distances are in 
the range of 2.05 - 2.09 Å. The structure overlay of the cations [Ru2L3]4+ and 
[Ru2L2-im3]4+ show that the imidazole-based complex is somewhat shorter (~2 Å) 
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than that of pyridine-based compound. However, due to the same spacer group 
in both ligands, the central part of the complex is relatively of the same size, 
therefore Ru atoms overlay perfectly in both structures (Fig. 2.14). 
 
 
Fig. 2.14 Overlay of crystal structures of [Ru2L3]4+ (grey) and [Ru2L2-im3]4+ (purple) 
 
The UV-Vis absorption spectrum of the helicate reveals MLCT band centered at 
475 nm (ε = 23 000 M-1 cm-1 in H2O) and excitation at this wavelength             
(λex = 475 nm) results in an emission band centered at 710 nm (Fig. 2.15). 
 
 
Fig. 2.15 Absorption (black) and emission spectrum (red) of [Ru2L2-im3]Cl4 recorded in water       
(λex = 475 nm). Spectra are not on the same scale. 
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Undertaking the reaction for shorter durations of time led to the formation 
of a second symmetrical product with very similar physicochemical properties to 
the triple-stranded helicate and with the same mass spectrum. The 1H NMR 
spectrum of the purified two co-existing compound(s) from the reaction (3 days 
of reflux) is shown in Fig. 2.16. When the duration of the reaction was 
shortened to one day only instead of three days the two products were obtained 
in a 1:2 ratio of the unidentified compound to helicate. Although multiple trials to 
separate the two compounds were undertaken using different stationary phases 
and solvent systems the full separation of the two compounds was 
unsuccessful. However, it was observed that extending the time of the reaction 
to 6-7 days results in the formation of helicate only (no second set of peaks was 
observed in the 1H NMR spectrum).  
 
 
Fig. 2.16 1H NMR spectrum of [Ru2L2-im3](PF6)4 (main peaks) with the second symmetrical 
product of the reaction. 
 
 
This might be an indication that the longer duration of the reaction leads to the 
degradation of the second, unidentified, product or its conversion into helicate. 
Given that the mass spectral data indicates an M2L34+ formulation and that the 
NMR indicates a highly symmetrical species, but its CH2 group appears as two 
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doublets, it would appear that a triple-stranded box, a mesocate,[29, 30] forms 
during the reaction. Moreover, if so then the triple-stranded mesocate may be a 
non-dissociative intermediate on the pathway to the triple-helicate, converting 
into a helicate by a Bailar or Ray–Dutt twist.[31] Due to the inert character of the 
Ru center the conversion would need very drastic conditions, like very high 
temperature and/or long duration of the reaction.  
 
2.2.5 Synthesis and characterisation of [Ru2L4(5)-im3]Cl4  
To explore whether the isomerism of the imidazole building unit can influence 
DNA-binding properties and cytotoxic activities of the cylinder the ligand L4(5)-im  
(Fig. 2.17) was used to prepare the second imidazole-based Ru cylinder.  
The ligand was synthesized using the procedure previously detailed by 
Pascu.[28] 
 
 
Fig. 2.17 Molecular structure of L4(5)-im. 
 
The ligand was prepared using the same diamine spacer moiety as in the ligand 
L2-im but the 2-imH aldehyde was replaced by 4(5)-imidazolecarboxaldehyde. 
The coordination of the L4(5)-im to Ru(II) centre was performed by a method 
analogous to that described for the [Ru2L2-im3]Cl4. The reaction between          
cis-[Ru(DMSO)4Cl2] and L4(5)-im was carried out at high temperature (200oC) for 
7 days and subsequent extraction and column chromatography led to obtain a 
pure product in a 1 % yield.  
N N
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Fig. 2.18 Aromatic region of the 1H NMR spectrum of [Ru2L4(5)-im3]Cl4 in MeOD 
. 
 
The 1H NMR spectrum shows seven proton resonances, which confirm the high 
symmetry of the system (Fig. 2.18). The mass spectrum shows a peak at m/z 
316.6 corresponding to the 4+ charged compound, [Ru2L4(5)-im3]4+, 421.7 that 
corresponds to [Ru2L4(5)-im3 – H]3+, and 632, which indicates [Ru2L4(5)-im3 – 2H]2+ 
formulation. 
Multiple attempts to crystallize the compound with different counterions and 
from different solvent systems were undertaken, however no diffraction was 
observed from the crystals obtained.  
The orange colour of [Ru2L4(5)-im3]4+ arises from the MLCT transitions, which are 
visible in the UV-Vis spectrum as a band centered at 423 nm.  When excited at 
375 nm an emission band with a maximum at 465 nm is observed (Fig. 2.19). 
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Fig. 2.19 Absorption (black) and emission (red) spectrum of [Ru2L4(5)-im3]Cl4 recorded in water 
(λex= 375 nm). Spectra are not on the same scale. 
 
 
2.3 DNA binding studies 
Having established the synthetic procedures for several new ruthenium 
cylinders and knowing that supramolecular cylinder have the potential to modify 
the DNA secondary structures, the binding properties of all three new helicates 
using a range of biophysical techniques has been initiated.  
Since the DNA-binding and further biological studies were to be undertaken in 
aqueous solutions the stability of the newly synthesized complexes had to be 
first determined. As seen in Fig. 2.20 the UV-Vis studies reveal that all three 
complexes are stable in aqueous solution. This is a valuable feature of 
ruthenium complexes and especially important for probing bio-molecular 
interactions and for biological studies.  
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Fig. 2.20 UV-Vis absorption spectra of (red) [Ru2Lo3]Cl4, (purple) [Ru2L2-im3]Cl4, (blue) 
[Ru2L4(5)im3]Cl4 recorded over a period of 24h in aqueous solution. 
 
 
2.3.1 Circular dichroism  
Circular dichroism (CD) is a UV-Vis absorption based spectroscopic 
technique that measures the differences in absorption of left and right hand 
circularly polarized light, which arise from the chirality of the molecule or its 
asymmetric character.[32]  
CD = AL - AR 
 
This spectroscopic technique is very useful and especially advantageous for 
providing the information about the structural features of biologically significant 
macromolecules in solution like proteins or nucleic acids, but also to monitor the 
macroscopic structural changes in the system while changing the environment 
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conditions or upon interaction with other chromophores and to assess their 
binding modes and affinities.  
 
The DNA itself, as a chiral molecule, has an inherent CD signal and this signal 
is dependent on its conformation (e.g. A, B, Z). The typical B-DNA spectrum 
consists of two bands, positive centered at ~ 275 nm and negative centered at 
~ 240 nm with zero based around 258 nm (Fig. 2.21). The spectrum results 
from the helical orientation of the aromatic bases and is ‘a superimposed result 
of all the couplings of the transitions occurring in all the bases’ and is also 
strongly affected by stacking interactions of the base pairs.[32] The bands 
observed around and below 190 nm originate from the chiral sugar moieties in 
the DNA backbone and there is no CD signal above 300 nm.  
 
 
Fig. 2.21 Circular dichroism spectrum of ct-DNA 
 
Non-chiral molecules have no inherent CD spectroscopy signal, however, if 
they bind to or interact with chiral molecules like DNA they will experience a 
chiral environment and induced CD signals may result (ICD). These will be 
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unique to the specific interaction and are most apparent on the spectrum in the 
region where the chromophore of the guest molecule(s) absorbs. This is a 
strong indication of an interaction between the two molecules. 
Consequently, to probe the asymmetry of the system in the presence of the 
newly synthesized Ru cylinders, circular dichroism studies with B-DNA have 
been undertaken. CD titration experiments of Ru(II) cylinders with calf thymus 
DNA were conducted at constant DNA concentrations (300 µM), in a buffer 
containing 20 mM NaCl and 1 mM sodium cacodylate. The CD profiles of        
ct-DNA in the presence of increasing amounts of ruthenium complexes are 
shown in Fig. 2.22. The additions of cylinders to the DNA solutions result in 
strong induced MLCT CD signals in the 300 – 600 nm region indicating 
cylinder-DNA interactions. The increases in the intensities of these bands are 
linear in each of the three individual cases and this suggests that each complex 
interacts with DNA in a single binding mode. The DNA region in the spectra 
also shows changes upon addition of the complexes. For [Ru2Lo3]Cl4 an 
increase of the positive band (275 nm) and decrease in the intensity of the 
negative band (245 nm) is observed and there is also a shift of these bands 
towards longer wavelengths. This effect could be the result of ‘additive induced 
CD signals’, due to the ligand-ligand transitions in the complex that overlap with 
the DNA bands, but it can also indicate the local unwinding of the DNA helix. In 
the case of imidazole-based complexes a decrease in the intensity of both the 
positive and negative bands is observed in each case. The retained shape of 
the DNA band upon interaction with all three complexes confirms that the        
B-DNA conformation is retained.  
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Fig. 2.22 CD spectra of DNA upon addition of (from top) [Ru2Lo3]Cl4, [Ru2L2-im3]Cl4 and 
[Ru2L4(5)-im3]Cl4 (220 – 300 nm - 2 mm pathlength cuvette, 300 – 600 nm - 1 cm pathlength 
cuvette). Ratios are indicated as DNA base to complex. 
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2.3.2 Linear dichroism 
Linear dichroism (LD) spectroscopy probes the electronic transitions of 
an oriented sample, which take place when linearly polarized electromagnetic 
radiation (parallel and perpendicular to an orientation axis) is applied.[32, 33] 
 
LD = AII – AL 
 
Linear dichroism can be a useful technique for probing the orientation, flexibility 
and conformation of the sample, but can also be utilized to study the molecular 
recognition processes.[34] In particular, LD can be very advantageous for 
exploring drug-biomolecule systems, as it provides key information about the 
binding geometries, therefore allowing for the determination of the alignment of 
a drug and the degree of orientation and flexibility of a biomolecular complex.    
The principal requirement for LD spectroscopy is that the sample be oriented 
along the same vector, which can be achieved by a number of methods such as 
stretching the film, flowing the sample or applying an electric field. In this work a 
Couette flow cell (Fig. 2.23) was used to achieve orientation of a long DNA 
polymer by viscous drag generated in the sample chamber. 
 
 
 
Fig. 2.23 Schematic representation of Couette cell used for linear dichroism measurements. 
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The LD spectrum of DNA is dominated by π–π* electronic transitions in the 
DNA bases, which are parallel to the nucleobases. This appears on the 
spectrum as a strong negative band with the minimum at 258 nm. The 
transitions within the DNA phosphodiester backbone result in the spectrum in 
the second negative band centered at 195 nm (Fig. 2.24).  
 
 
Fig. 2.24 Linear dichroism spectrum of calf thymus DNA 
 
 
On interaction of the small molecules with DNA perturbations in the DNA LD 
signal(s) can be observed and, in addition, LD bands from the small molecule 
can appear in the spectrum. The latter will only happen if the small molecule 
becomes orientated due to its interaction with the DNA macromolecule. To 
probe these effects the linear dichroism titrations have been performed. 
Flow linear dichroism experiments were performed under the same condition as 
used in the CD titrations described above (300 µM ct-DNA, 20 mM NaCl, 1mM 
sodium cacodylate buffer). The LD titration spectra are shown in Fig. 2.25.  It is 
apparent that in all three cases upon addition of the complex the magnitude of 
the signal in the DNA region (259 nm) decreases. This is consistent with loss of 
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the DNA orientation, presumably a result of bending/kinking or coiling of the 
polymeric DNA by the helicates.  
 
 
 
Fig. 2.25 LD spectra of ct-DNA (300 µM, 20 mM NaCl, 1 mM sodium cacodylate) in the 
presence of (from top) [Ru2Lo3]Cl4, [Ru2L2-im3]Cl4, [Ru2L4(5)-im3]Cl4. Mixing ratios are indicated as 
DNA base to complex. 
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However, the degree of DNA coiling induced by interacting cylinders seems to 
be distinct for each complex (Fig. 2.26). The [Ru2Lo3]Cl4 has the greatest effect 
on DNA orientation and this complex also appears to give rise to DNA coiling 
via different pathway to that of the two imidazole-based complexes.  
 
 
Fig. 2.26 % LD signal of DNA at 258 nm upon addition of (from top) [Ru2Lo3]Cl4, [Ru2L2-im3]Cl4 
and [Ru2L4(5)-im3]Cl4.   
 
 
Addition of the cylinders to solutions of DNA results also in strong, induced 
positive LD signals in the cylinders MLCT regions, which increase 
systematically as more complex is added. This indicates that all compounds 
bind to polymeric DNA and the binding takes place in a specific orientation. The 
positive signs of these bands may suggest that cylinders are aligned more 
parallel than perpendicular to an orientation axis, which could be consistent with 
groove binding.  
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2.3.3 Agarose gel mobility shift assay 
The agarose gel mobility shift assay is a technique used in molecular 
biology to separate and analyze biomolecules by their size and/or 
conformation.[35] To probe the effect of the studied ruthenium triple-stranded 
helicates on the superhelical DNA structure and assess their DNA helix 
unwinding potential a series of electrophoretic mobility shift assays have been 
performed. The DNA used in these studies was the negatively supercoiled 
pBR322 plasmid consisting of 4361 base pairs.  
The plasmid DNA exists in two major forms: circular and supercoiled     
structure (Fig. 2.27).[36] However, upon interaction with other molecules, often 
as a result of the formation of a molecular complex, perturbations in the 
superhelical structure of the DNA may occur. These processes can be probed 
by the electrophoretic analysis of DNA.  
 
Fig. 2.27 Supercoiling: its handedness and sign. Adapted by permission from Macmillan 
Publishers Ltd: EMBO reports, 2004, 5, 256, copyright (2004). 
http://www.nature.com/embor/index.html 
 
Fig. 2.28 shows electrophoresis gels, in which pBR322 plasmid DNA has been 
mixed with increasing amounts of ruthenium complexes. It is apparent that as 
the concentration of Ru complexes increases the migration rate of the supercoiled 
DNA bands gradually decreases. It subsequently reaches the coalescence 
point, where all DNA supercoils are transformed to relaxed form, and after this 
review
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active on the bulk of cellular DNA that is maintained at physiologi-
cal levels of (–) supercoiling. Non-physiologically strong (–) super-
coiling or the presence of single-stranded regions activate topo I and
III (Champoux, 2001). Type II topoisomerases make transient double-
stranded breaks and allow the passage of another duplex across the
break. They are usually ATP-dependent (Gellert et al, 1976). There
are two type II topoisomerases in E. coli, which are known as DNA
gyrase and topo IV (Champoux, 2001). As with E. coli type I topo-
isomerases, gyrase and topo IV are also hardly active on the bulk of
cellular DNA and become activated by DNA relaxation in the case
of gyrase and by (+) supercoiling in the case of topo IV. It is important
for energy balance that there is no futile action of topoisomerases on
the bulk of DNA through which a gyrase, for example, would con-
tinuously use ATP to introduce (–) supercoiling and topo I or III
would relax the DNA. Topoisomerase action therefore needs to be
limited to the biological processes that involve DNA, such as repli-
cation, transcription, recombination and repair during which DNA
topology needs to be modified.
Tug-of-war between (–) and (+) supercoiling
To initiate their replication, bacterial plasmids must be (–) supercoiled
as this facilitates strand separation at the origin of replication (Fig 1A;
Funnell et al, 1987; Marians et al, 1986). Once initiation has been
accomplished, elongation proceeds by means of a complex ensemble
of enzymes known as the replisome. The current view is that during
replication, DNA passes through a stationary replisome. In front of this
replisome, a hexameric DNA helicase separates the parental strands
that are to be used as templates. This strand separation leads to over-
winding (positive supercoiling) of the duplex ahead of the fork (Fig 1A;
Alexandrov et al, 1999; Peter et al, 1998; Ullsperger et al, 1995).
However, (–) supercoiling is important for the opening of the DNA
double helix (Crisona et al, 2000; Kanaar & Cozzarelli, 1992). How
then do replication intermediates (RIs) manage to remain (–) super-
coiled as the fork advances? The first clue to answer this question came
with the discovery of DNA gyrase (Gellert et al, 1976). It is thought that
the continuous action of gyrase on the unreplicated portion of repli-
cating plasmids decreases the linking number of the parental duplex
(Alexandrov et al, 1999; Peter et al, 1998; Ullsperger et al, 1995). In
this way, gyrase helps to compensate for the overwinding of the
duplex as the fork advances. The rate of unlinking by gyrase, however,
is slow and might be insufficient to sustain the rate of fork movement
in E. coli (Peter et al, 1998). Furthermore, DNA gyrase can actively
cause unlinking only when acting on the unreplicated portion of repli-
cating plasmids (Gellert et al, 1976; Kampranis et al, 1999). At early
stages of replication, when the unreplicating portion is sufficiently
long, several gyrase molecules could work in parallel to sustain a high
speed of unlinking. As the length of the unreplicated portion shrinks,
however, there is less space for gyrase to act. Each gyrase molecule
needs around 150 base pairs to bind to DNA (Bates & Maxwell, 1989),
and so overwinding caused by the progressing fork may eventually
accumulate. This potential problem was first recognized by James
Champoux and Michael Been (Champoux & Been, 1980), who real-
ized that this gyrase deficit would eventually lead to the accumulation
of (+) supercoiling at later stages of the replication process. To solve
this dilemma, they proposed that supercoiling might diffuse through-
out the replication fork and redistribute both ahead of and behind the
fork. In this model, the other type II topoisomerase, topo IV, which is
the main decatenase in E. coli (Zechiedrich & Cozzarelli, 1995;
Zechiedrich et al, 1997), assists gyrase to compensate for the over-
winding that accumulates as the fork advances. Brian Peter and co-
workers (Peter et al, 1998) used electron microscopy to confirm the
diffusion of supercoiling across the fork in an in vitro assay that yielded
partially replicated plasmids containing stalled forks. They called the
intertwining of the sister duplexes in the replicated portion “precate-
nanes” to distinguish them from the supercoiling in the unreplicated
portion (Figs 2A and 3B,D,E). The emerging idea was that unlinking of
the parental duplex during DNA replication is carried out by gyrase
introducing (–) supercoils ahead of the fork and topo IV removing pre-
catenanes behind the fork. This would explain why progression of the
replication fork is impeded when both gyrase and topo IV are mutated
B
-
-
Clockwise Counterclockwise
+
+
A
-
-
-
+
+
+
+
-
Fig 1 | Supercoiling: its handedness and sign. (A) Negatively supercoiled DNA (left) loses supercoiling due to local DNA unwinding mediated by DNA helicases
(shown as grey wedges) and then becomes (+) supercoiled by further strand separation.Notice that the intertwined superhelix is right-handed in (–) supercoiled
molecules and left-handed in (+) supercoiled ones. The sign of the duplex–duplex crossings (see panel B) changes from (–) to (+) upon a change from negative to
positive supercoiling. (B) Topological convention of sign assignment of perceived crossings. In a (–) crossing,one would need to turn the overlying direction
arrow clockwise to align it with the underlying direction arrow (the rotation needs to be smaller than 180°). In a (+) crossing the required rotation would be
counterclockwise.Notice that orientation of the underlying and overlying direction arrows at each crossing are not independent from each other but result from
assigning a consistent direction along the whole DNA molecule analysed. To facilitate sign recognition in A and B, the overlying and underlying direction arrows
are marked in red and blue, respectively.
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stage positive supercoiling is induced, resulting in an increase of the DNA 
migration rate.  
 
 
Fig. 2.28 Agarose gel electrophoresis of circular plasmid pBR322 after 1h of incubation with 
increased amount of complex a) [Ru2Lo3]Cl4 lanes 1-11, rb = 0.023, 0.025, 0.027, 0.031, 0.036, 
0.038, 0.042, 0.045, 0.050, 0.060, 0.083, 0.125, 0.25; b) [Ru2L2-im3]Cl4 lanes 1-10, rb= 0.05, 
0.055, 0.06, 0.07, 0.08, 0.10, 0.125, 0.17, 0.25, 0.50; c) [Ru2L4(5)-im3]Cl4 lanes 1-10, rb= 0.05, 
0.055, 0.06, 0.07, 0.08, 0.10, 0.125, 0.17, 0.25, 0.50; C- control, sc – supercoiled DNA, oc – 
open circular DNA. 
 
Using the coalescence points, on the assumption that at this stage all cylinders 
are bound to the DNA, the degree of DNA unwinding per bound drug, 
unwinding angle (φ), can be calculated:[37] 
φ = 18 ⋅ σ / rb(c) 
 
where φ is the unwinding angle, σ is the superhelical density and rb(c) the 
number of cylinders bound per DNA base for which the supercoiled and  
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circular forms of plasmid co-migrate. Based on the DNA unwinding angle for 
cisplatin (13o)[38] σ was found to be -0.059 and rb values were determined from 
the DNA to complex mixing ratios. The calculated unwinding parameters for the 
studied cylinders are summarized in Table 2.1.   
 
Compound rb(c) unwinding angle (o) 
[Ru2L3](PF6)4 0.08 13  
[Ru2L3]Cl4 0.042 25 
[Ru2Lo3]Cl4 0.06 17  
[Ru2L2-im3]Cl4 0.13 8 
[Ru2L4(5)-im3]Cl4 0.25 4 
 
Table 2.1 DNA unwinding angles of Ru(II) triple helicates 
 
 
The results herein demonstrate that all cylinders interact with DNA and relax 
negative supercoils to different extents, which confirms that all complexes 
interact with DNA dissimilarly. Of the three new Ru(II) helicates, [Ru2Lo3]Cl4 
appears to have the greatest unwinding properties (17 ± 3o). This may indicate 
that [Ru2Lo3]Cl4, while adopting a major groove binding, has a greater degree of 
insertion into the groove than [Ru2L2-im3]Cl4 and [Ru2L4(5)-im3]Cl4, possibly by 
‘fitting’ one of the ligands between DNA bases. This effect might be      
restricted in the case of the imidazole-based helicates due to the additional -NH 
groups present at the metal-binding units, which could form hydrogen bonds 
with the phosphate backbone and thus limit the groove penetration. The 
position of -NH groups in the imidazole ring may also have an effect in the 
recognition process. 
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2.4 Cell viability assay 
It has been shown that supramolecular cylinders possess promising 
anticancer activities against several human cancer cell lines.[39] In order to 
explore the anticancer properties of the new cylinders and access their possible 
structure-activity relationship, MTT cell proliferation assays have been 
performed. The MTT assay is a colorimetric assay used for quantification of the 
activity of reductase enzymes that convert MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, to formazan in viable cells (Fig. 2.29), 
therefore allowing for the evaluation of the mitochondrial activity in metabolically 
active cells.  
 
 
Fig. 2.29 Reduction of MTT to formazan crystals. 
 
 
All three complexes were preliminarily tested in vitro for their cytotoxic activities 
against human breast cancer cell lines (T47D and MDA-MB-231) and the IC50 
values were determined from the concentration-response curves. The results 
are shown in Fig. 2.30 (See also Table 2.2). The obtained IC50 values for 
[Ru2L3]Cl4 and [Ru2Lo3]Cl4 are very similar ~ 55 – 60 µM, which indicates that 
introducing the oxygen bridge in the centre of the ligand does not remarkably 
influence the cytotoxicity of the cylinder.  
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Fig. 2.30 IC50 values of ruthenium cylinders tested in breast cancer cell line (T47D). 
 
 
However, changing the coordination sphere of ruthenium from pyridine to 
imidazole, while maintaining the shape of the cylinder seems to be causing a 
dramatic increase of the cytotoxicity of the cylinder. [Ru2L4(5)-im3]Cl4 is around 
two-fold more cytotoxic (IC50 = 29 ± 3 µM) than its pyridine analogue and initial 
testing of the second imidazole complex, [Ru2L2-im3]Cl4, shows that this 
compound also exhibits much greater cytotoxicities than pyridine-based 
complexes (IC50 = 35 ± 4 µM). 
 
Compound IC50 (µM) 
cisplatin 22 ± 1 
[Ru2L3]Cl4 59 ± 10 
[Ru2Lo3]Cl4 56 ± 7 
[Ru2L2-im3]Cl4 35 ± 4 
[Ru2L4(5)-im3]Cl4 29 ± 3 
 
Table 2.2 IC50 values of Ru cylinders tested in breast cancer cell line (T47D) 
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2.5. General discussion, conclusions and further work  
New and improved methodologies for the synthesis and purification of 
the ruthenium triple-stranded helicates have been developed. Three new, stable 
and fluorescent ruthenium cylinders have been prepared and characterised and 
studies of their DNA binding properties and biological activities have been 
undertaken.   
There are two important properties of the supramolecular helicates 
common to all three studied cylinders which are very important for the formation 
of their molecular complexes with DNA: the relatively large hydrophobic surface 
and cationic charge (+4). These two features are anticipated to have a 
substantial energetic contribution to the overall Gibbs free energy of the system 
and have a major impact on the thermodynamic characteristics of the system 
thus driving the formation of a molecular complex. The intermolecular 
supramolecular interactions between the helicates and the DNA i.e. hydrogen 
bonding, Van der Waals interactions and possibly π - π stacking are also 
expected to have a favorable energetic contribution to the binding free energy. 
Nevertheless, as anticipated from the linear dichroism studies and agarose gel 
mobility shift assays, the structural features of the three studied complexes and 
their ability to interact non-covalently with certain biomolecule moieties seems 
to have a great impact on the DNA secondary structure. While all complexes 
bind to and coil the polymeric DNA and cause unwinding of the supercoiled 
DNA, the magnitude of the structural changes caused by each complex is 
distinct. Both the DNA coiling and unwinding properties decrease as follows 
[Ru2Lo3]Cl4 > [Ru2L2-im3]Cl4 > [Ru2L4(5)-im3]Cl4.  
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The cytotoxicity testing of the three ruthenium helicates proved that all 
complexes exhibit antiproliferative properties in human cancer cell lines with 
IC50 values below 60 µM. Interestingly, imidazole-based complexes seem to be 
around two-fold more cytotoxic than their pyridine analogues. The reason for 
this effect is not understood as yet and further, extensive cytotoxicity testing 
should be a feature of further investigations.  
The cellular responses of supramolecular cylinders are believed to be due to 
their DNA binding properties, therefore full understanding of the molecular 
interaction between the complex and DNA at the structural, thermodynamic and 
kinetic level is crucial in order to obtain a full, detailed picture of the drug-DNA 
binding. In addition to the more detailed structural studies on the cylinder-DNA 
complex the investigation of the binding affinities and energetics of the 
molecular complex formation should be performed.  
To access possible structure-activity relationships of the new compounds the 
effect of isomerism of the imidazole complexes should be explored. Preparation 
of modified cylinders such as these containing oxazole or N-substituted 
imidazole as the metal binding unit and studies of their biomolecule-binding 
properties and cytotoxic activities should be performed. 
Further, more comprehensive cytotoxicity testing of the studied systems should 
be undertaken in order to explore the activities of these compounds in different 
cancer cell lines and to compare their effects. Following this, the studies of the 
uptake, cellular distribution, genotoxicity and finally mutagenicity of the new 
cytotoxic complexes should be performed. 
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3 
Optical Isomers of  
Ru(II) Triple-Stranded Helicate  
 
 
 
 
 
 
 
Abstract  
 
In this chapter the separation and characterisation of optical isomers of ruthenium triple-
stranded helicates of a formula [Ru2L3]Cl4, where L is bispyridylimine ligand 
(C6H4N)C=N(C6H5)CH2(C6H5)N=C(C6H4N), is presented. Both enantiomers have also been 
tested for their DNA binding properties using linear dichroism, fluorescence and agarose gel 
mobility shift assay. Both isomers interact with DNA, inducing coiling of duplex DNA and 
extensive unwinding of supercoiled DNA. The effect of the M enantiomer on DNA structure was 
found to be greater than that of its P analogue, consequently its binding constant was found to 
be higher.  
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3.1 Introduction 
In recent years the importance of chirality has been widely explored in 
the field of supramolecular recognition. This is due to its considerable potential 
impact on the areas of bio- or nanotechnology, medicinal chemistry and drug 
development. Stereochemistry can play a critical role in determining the 
strength and selectivity of molecular recognition, therefore the asymmetric 
nature of the binding molecule can be a valuable tool in the recognition of 
biologically important molecules like DNA or RNA, but also in the recognition of 
synthetic nucleic acids such as PNAs.[1] In this field, chirality can be particularly 
effective for examining local alterations in nucleic acids structures but also for 
probing their conformational features.[2] For example, the Δ-enantiomer of 
[Ru(DIP)3]2+ (DIP-4,7-diphenyl-1,10-phenanthroline) (Fig. 3.1) was shown to 
preferentially recognize B-DNA while its Λ-stereoisomer favours binding to left-
handed Z-DNA.[3] 
 
 
 
Fig. 3.1 Molecular structure of Δ-[Ru(DIP)3]2+ 
 
N
N
N
N
N
N
Ru
2+
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As highlighted by Barton,[4] the chiral discrimination in this kind of systems i.e. 
intercalators with DNA, is contingent upon the symmetry of the metal complex 
corresponding to that of the biomolecule.  
  
Stereochemistry has also had a great impact on drug design and 
development.[5] The asymmetric properties of a potential therapeutic agent may 
play a crucial role in its action and biological activity and furthermore its cellular 
uptake, metabolism and/or delivery to the biological target may also be affected. 
However, the inherent features of chiral molecules include their potential for 
chiral inversion or racemisation, as seen in the case of thalidomide. This can 
have severe consequences for biological processes, hence studies of the 
nature of enantiopure drugs, their biomolecule recognition properties and 
cellular effects is mandatory. 
 
The dinuclear triple-stranded complexes of the types described in Chapter 2 
have a size and shape comparable to protein zinc-finger DNA recognition motifs 
and since these complexes adopt a helical structure, possess chiral properties      
(Fig. 3.2). Indeed the asymmetric character of supramolecular cylinders is 
distinct from this of intercalating agents, thus their molecular recognition 
properties and biological effects are unique yet not fully understood. 
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Fig.3.2 The optical isomers of the dinuclear triple-stranded helicates with bispyridylimine ligand; 
(left) left-handed M enantiomer, (right) right-handed P enantiomer. 
 
Studies had been undertaken previously to explore the effect of the two 
enantiomers of an iron(II) helicate on the DNA structure.[6] It was found that both 
enantiomers bind strongly to the DNA, however the binding effects of the         
M-(ΛΛ)-enantiomer seemed to be the greater of the two. It was concluded that 
the two enantiomers bind strongly to natural polymeric DNA but might possess 
different binding modes. While the M enantiomer has been found to bind in the 
major groove of the duplex DNA, the location of the P enantiomer was less 
clear: it could also be binding in the major groove but has been proposed to be 
binding on top of the minor groove spanning the two phosphate backbones. 
More recently, Brabec and co-workers explored the chiral dinuclear Fe triple-
helical systems for their interactions with DNA three-way junctions and found 
that the M enantiomer is more efficient in stabilization of these structures than 
the corresponding P enantiomer.[7] 
The aim of the work presented in this chapter is to investigate and understand 
the binding effects of two enantiomers of ruthenium(II) triple-stranded helicate 
with the bispyridylimine ligand (Fig. 3.3) towards DNA structures. This is not 
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only to see how the complexes with different asymmetric properties interact with 
DNA, but also to understand the role of the metal center in the overall binding 
properties of the helicates.  
 
 
Fig. 3.3 Bispyridylimine ligand L 
 
 
3.2 Results and discussion  
3.2.1 Enantiomer separation 
The compound, which is the subject of these studies, [Ru2L3]Cl4 was 
synthesized and purified as a racemic mixture according to the procedure 
described in Chapter 2. 
 
Separation of optically active species often involves the application of 
chiral ions for diastereoselective ion-pairing either in crystallization or extraction 
processes or in the chromatographic resolution on the stationary phase, where 
chiral ions serve as key components of the mobile phase.[8] These techniques 
give a very efficient resolution of chiral organic molecules, optical isomers of 
mononuclear polypyridyl metal complexes,[9] but can also be successfully used 
for the separation of more subtle structures like multinuclear metal-based 
helical arrangements.[10-12] Chiral stationary phases in column chromatography 
can also be employed for the resolution of these systems. Hannon et al. 
showed that simple paper chromatography and a 20 mM aqueous solution of 
N N
N N
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NaCl can afford the separation of two enantiomers of metallo-supramolecular 
helicates.[13] It was also found that this technique could be applied on the 
preparative scale using cellulose chromatography for the purification and 
resolution of enantiomeric helicates with different structural topologies.[14]  
To initiate this work the separation of the two optical isomers of ruthenium triple 
stranded helicate, [Ru2L3]4+, using the cellulose approach was explored. In all 
attempts the compound was used as an analytically pure sample in its chloride 
form.  
The first explored approach for the resolution of Ru enantiomers was based on 
the Hannon technique, which employed cellulose (~20 micron) and 20 mM 
aqueous solution of NaCl as an eluent. Although in this method a partial 
resolution of enantiomers was obtained, the technique itself was found to be 
very inefficient for the separation of ruthenium triple-stranded helicates. As 
observed earlier for the iron cylinder, the two bands that formed after applying 
the eluent remained partially merged throughout the whole separation process 
and a part of a loaded compound remains on the column. This necessitated 
repeat column chromatography with a consequent loss of the compound and as 
a result of this only 5-10 % of the amount of initially loaded compound could be 
recovered as enantiopure isomers.  
Further investigations led to the finding that using the same stationary phase 
(~20 micron cellulose) but increasing the concentration of eluent by 10 fold     
(0.2 M aq. NaCl) and introducing medium pressure on top of the column leads 
to the clear separation of the loaded compound into two distinct orange bands. 
It was also found that using this method no loss of the compound on the column 
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is observed and a total of 96 % of initially loaded complex can be eluted. These 
conditions also give clear separation for the iron cylinder.  
The two obtained fractions were further examined using NMR, MS and UV-Vis 
spectroscopy and confirmed that the two enantiomers have been separated. 
The CD spectra of the two separated compounds, for the same absorbance, 
are identical in shape, equal in magnitude and opposite in sign throughout the 
whole range of the spectrum (Fig. 3.4), suggesting that complete separation of 
the optical isomers was achieved. The enantiopurity of the obtained fractions 
was further investigated and confirmed by NMR studies with Δ-TRISPHAT as a 
chiral shift reagent (see Chapter 4). 
 
Fig. 3.4 UV-Vis absorption spectrum of [Ru2L3]4+ (left) and CD spectra of M- and P-[Ru2L3]4+ 
(right) in H2O. 
 
Total absolute configurations of the two enantiomers of [Ru2L3]Cl4 were 
assigned from the CD spectra. On the basis of exciton theory and model 
compounds[15-17] the first eluted compound was found to be left-handed,        
ΛΛ-(M)-[Ru2L3]4+ and the second right-handed ΔΔ-(P)-[Ru2L3]4+. Further 
confirmation of this assignment comes from the X-ray structure detailed below.  
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The kinetic stabilities of both enantiomers in aqueous solution were measured 
by UV-Vis and CD spectroscopy. As expected, due to the high kinetic stability of 
Ru polypyridyl complexes, after four weeks at room temperature no changes in 
absorbance or optical activity were observed in either solution. This indicates 
that optically pure Ru triple-stranded helicates are configurationally stable and 
do not undergo racemisation in aqueous solution.  
 
 
3.2.2 X-ray structure 
X-ray quality crystals of the second eluting P enantiomer were 
successfully obtained by slow diffusion of diethyl ether into a methanolic 
solution of the chloride form of the compound at 4oC. The compound 
crystallized in the cubic crystal system with the enantiomorphic space group 
I213. The crystal structure shows that both metal centers adopt a Δ 
configuration and thus the overall molecule is right-handed (Fig. 3.5). 
 
 
Fig. 3.5 Crystal structure of cation in P-[Ru2L3]Cl4: side view (left), top view (right). The 
hydrogen atoms, counter ions and solvent molecules are omitted for clarity. 
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3.3 DNA binding studies 
Having established an efficient methodology for the total resolution of 
optically active isomers of ruthenium triple-stranded helicate and determined 
their properties and solution behaviour an investigation of the DNA binding 
characteristics of both enantiomers has been initiated.  
 
3.3.1 Flow linear dichroism spectroscopy 
The LD studies of the effect of a racemic mixture of [Ru2L3]Cl4 on ct-DNA 
showed that the metallo-helicate causes a dramatic loss of the DNA orientation, 
which was consistent with bending or coiling of the DNA.[18] To explore the 
binding/bending effects of the enantiopure isomers and compare them to the 
effect of the racemate the LD titration experiments with ct-DNA were  
performed. The experiments were carried out with a constant DNA 
concentration (300 µM) in the buffer containing 20 mM NaCl and 1 mM sodium 
cacodylate. The linear dichroism titration spectra are illustrated in Fig. 3.6.  
The effect of both enantiomers, M-[Ru2L3]4+ and P-[Ru2L3]4+, on DNA structure 
is remarkable and it is apparent that with an increase of the cylinder 
concentration a systematic loss of LD signal at 258 nm occurs. Both isomers 
cause the loss of the magnitude of the DNA LD signal, consistent with either an 
increase in DNA flexibility or compound-induced kinking, bending or coiling of 
DNA, which could also be related to DNA aggregation or compaction.  
However, it is nonetheless evident that the M enantiomer has a more dramatic 
effect on DNA coiling/bending than its P analogue.  
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Fig. 3.6 LD spectra of ct-DNA (300 µM, 20 mM NaCl, 1 mM sodium cacodylate) upon addition 
of (from top) rac-, M- and P-[Ru2L3]Cl4. Mixing ratios are indicated as DNA base to complex. 
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At a 60 : 1 ratio (DNA base : complex) a 25% loss of DNA LD signal is observed 
in the case of the M enantiomer and only a 6% decrease in the case of the P 
enantiomer. At a 6 : 1 ratio of DNA base to complex (10 times higher cylinder 
concentration) M-[Ru2L3]4+ causes almost total loss of the DNA signal (98 %). 
This indicates stronger kinking of the DNA compared to the P enantiomer, 
which at the same ratio causes only 65% signal loss (Fig. 3.7). The racemic 
mixture induces a 15 and 82 % loss of LD signal at above ratios, which seems 
to be a combination of the effects of M and P helicates. This suggests that both 
enantiomers interact with the biomolecule independently.  
Similar effects on DNA structures of left and right-handed helicates were 
observed for the M- and P-[Fe2L3]4+ in the previous studies by Meistermann et 
al.. M-[Fe2L3]4+ was found to cause more dramatic kinking than the P 
enantiomer.[6]  
 
 
Fig. 3.7 % LD upon addition of increased amount of complexes. 
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Moreover, the supramolecular cylinders do not bind to DNA randomly yet in an 
oriented manner. As more complex is added to the DNA sample induced LD 
signals in the MLCT region appear in the spectra and increase gradually as the 
cylinder concentration increases. Although both enantiomers acquire orientation 
upon binding to the DNA the magnitude of the induced positive band at 485 nm 
is remarkably higher for P enantiomer. Indeed the positive signs of these bands 
indicate that the cylinders bind more parallel than perpendicular to the 
orientation axis, which would be consistent with groove binding. Interestingly, in 
the 300 – 400 nm region additional induced bands appear on the spectra upon 
addition of complexes and these have opposite signs for both enantiomers, 
positive for the M enantiomer and negative for the P enantiomer. 
 
3.3.2 Fluorescence response 
In the previous studies on the racemic mixture it was found that the 
ruthenium cylinder, when excited in the MLCT region (485 nm), gives rise to an 
emission band centered around 700 nm and upon binding to DNA this 
fluorescence is enhanced.[18] Therefore, having established through LD that the 
enantiomers have distinct effects on the structure of ct-DNA, causing different 
coiling effects, further spectroscopic studies were undertaken to determine the 
binding affinities of both enantiomers to ct-DNA. The fluorescence response of 
both enantiomers and a racemic mixture were studied as a function of 
increasing the DNA to cylinder ratio while maintaining the cylinder concentration 
constant (Fig. 3.8). 
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Fig. 3.8 Fluorescence response of rac-, M- and P-[Ru2L3]Cl4  (λex=485 nm), (25 µM, 20 mM 
NaCl, 1 mM sodium cacodylate) upon addition of ct-DNA. Mixing ratios are indicated as 
complex to DNA base. 
 
 
It is apparent that the emission intensity of both enantiomers in aqueous 
solution increases concomitantly with an increase in the DNA to cylinder ratio 
(Fig. 3.9). This effect is due to DNA providing shielding for the excited state of 
Ru complex from quenching by water molecules.[19, 20] However, the 
fluorescence enhancement is greater in the case of M-[Ru2L3]4+, which indicates 
that the M enantiomer is better protected by DNA than P isomer. This implies a 
higher binding equilibrium constant (Kb) for M-[Ru2L3]4+.  
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Fig. 3.9 Fluorescence response of rac-, M- and P-[Ru2L3]4+ upon addition of  increasing amount 
of ct-DNA. 
 
 
Scatchard analysis of the emission titration data allowed for determination of 
the equilibrium binding parameters of the excited-state Ru(II) complexes with  
ct-DNA (Table 3.1). 
 
Compound  Kexb (M-1)  
    
rac-[Ru2L3]Cl4  2.24 ± 0.9 x 105  
M-[Ru2L3]Cl4  3.10 ± 0.4 x 105  
P-[Ru2L3]C4  1.94 ± 0.5 x 105  
 
Table 3.1 Equilibrium parameters for rac-, M-, and P-[Ru2L3]Cl4 obtained from fluorescence 
titrations (each value represents the average of the values obtained from three independent 
experiments, errors represent standard deviations). 
 
 
The analysis indicated that equilibrium binding constants of the ruthenium(II) 
triple-stranded helicate are greater than 105 M-1. Interestingly, these results are 
consistent with the binding affinities of quaterpyridine-based tetracationic Ru(II) 
triple-stranded helicates obtained by Glasson.[11]  
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The equilibrium binding constants of the two enantiomers M and P were found 
to be 3.10 ± 0.4 x 105 M-1 and 1.94 ± 0.5 x 105 M-1 respectively. The P 
enantiomer seems to have a lower binding affinity compared to its M analogue 
and in thermodynamic terms this would suggest higher values of Gibbs free 
energies associated with formation the of P-[Ru2L3]4+- DNA adduct compared to 
that of the M-[Ru2L3]4+-DNA system. The approximate calculations gave rough 
evaluation of the free energies of the formation of the helicate-DNA molecular 
complexes. These were found to be -30.5 kJ mol-1, -31.2 kJ mol-1 and                
-30.0 kJ mol-1 for racemic mixture, M and P enantiomer respectively. It is also 
apparent that the cylinder to DNA binding events proceed spontaneously (at 
room temperature) hence move the systems to lower, more thermodynamically 
stable energy states.  
 
3.3.3. Agarose gel mobility shift assay 
The unwinding effects of the negatively supercoiled plasmid DNA 
pBR322 upon interaction with the Ru cylinders was determined by agarose gel 
mobility shift assay as described in Chapter 2.  
Figure 3.10 presents the electrophoresis gels of the plasmid-cylinder 
complexes, where the plasmid has been mixed with increasing amounts of     
rac-[Ru2L3]Cl4, M-[Ru2L3]Cl4 and P-[Ru2L3]Cl4. Both enantiomers greatly unwind 
supercoiled DNA. M-enantiomer is more efficient in unwinding negatively 
supercoiled DNA than the P-enantiomer, though effects of both are similar to 
these observed for the corresponding Fe cylinders (32 ± 3o and 22 ± 3o for M- 
and P-[Fe2L3]4+ respectively).[21]  
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Fig.3.10 Agarose gel electrophoresis of circular plasmid pBR322 after 30 min of incubation with 
increased amount of complex:  (black) rac-[Ru2L3]Cl4 lanes 1-12, rb = 0.023, 0.028, 0.031, 
0.033, 0.036, 0.038, 0.042, 0.045, 0.050, 0.056, 0.071, 0.167; (green) M-[Ru2L3]Cl4 lanes 1-11, 
rb = 0.014, 0.02, 0.024, 0.028, 0.031, 0.033, 0.036, 0.038, 0.045, 0.071, 0.100; (blue) P-
[Ru2L3]Cl4 lanes 1-12, rb = 0.028, 0.033, 0.036, 0.038, 0.042, 0.045, 0.05, 0.056, 0.063, 0.071, 
0.100, 0.250; C- control, sc – supercoiled DNA, oc - open circular DNA. 
 
 
The calculated unwinding angles are listed in Table 3.2 
 
Compound rb (c) unwinding angle (o) 
rac – [Ru2L3](PF6)4 0.08 13 ± 2 
rac – [Ru2L3]Cl4 0.042 25 ± 3 
M – [Ru2L3]Cl4 0.031 34 ± 3 
P – [Ru2L3]Cl4 0.045 23 ± 4 
 
 
Table 3.2 Coalescence points and unwinding angles for rac-, M- and P-[Ru2L3]Cl4 (each value 
represents the average of the values obtained from three independent experiments, errors 
represent standard deviations).  
 
 
The effect of rac-Ru cylinder on the superhelical DNA structure is presumably a 
combination of the effects of M and P helicate and, consistently with the linear 
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dichroism experiments, might indicate that both, left- and right-handed isomers 
interact independently with DNA. These results are also comparable to the 
results obtained for the rac-iron helicate (27 ± 3o).[21] However, Malina et al. 
found that when plasmid DNA was treated with rac-[Ru2L3](PF6)4 (instead of the 
chloride salt of this complex, as studied here) the complex unwinds the 
supercoiled DNA by 13o only,[22] which is only half of the effect observed for the 
chloride counterpart of the complex. This suggests the contribution of the 
counterion in the metal complex to the local unwinding of DNA.  
 
3.4 General discussion, conclusions and further work 
Recognition of DNA by supramolecular cylinders is expected to be 
predominantly driven by hydrophobic interactions and/or electrostatic attractions 
i.e. entropically favorable polyelectrolyte effects between the cylinder and 
polyanionic DNA. These two elements give a substantial contribution to the 
Gibbs free energy of the cylinder-DNA complexation. Although the tetracationic 
charge and large hydrophobic surface are common to both optical isomers, the 
different asymmetric character of the two enantiomers and thus different binding 
potential, gives rise to distinctive effects on DNA and thus should be reflected in 
the thermodynamics of the systems. The energetics of the drug – DNA binding 
event is a function of several factors, such as hydrophobic effects, 
polyelectrolyte effects, reorganization of water molecules, DNA structural 
changes, intermolecular interactions etc., all of which give rise to the distinctive 
energy gains and losses of the system and this is reflected in the binding 
affinities of the drug towards DNA and therefore in the stability of the system.  
 101 
As discussed in previous paragraphs, the formation of [Ru2L3]4+-DNA 
complexes gives rise to significant changes in the DNA secondary structure and 
these are remarkably different for both optical isomers of [Ru2L3]4+. The linear 
dichroism studies showed that the M enantiomer has a greater effect on DNA 
structure than its corresponding P enantiomer, causing over 30 % more 
dramatic coiling of the DNA duplex compared to the effect of the P enantiomer 
at the same DNA base to complex ratio. This might be a consequence of more 
favourable shape features of the M enantiomer, which could fit deeper into the 
DNA groove and interact with the DNA bases either by inserting one its   
ligands between the stacked bases or alternatively by face to edge π-π 
interactions between the phenyl rings and DNA bases. The P enantiomer, 
assuming that it also adopts major groove binding, would be expected to be 
sterically hindered from these types of contacts and consequently the 
magnitude of the free energy component of non-covalent interaction of this 
class in this case would be different. The structural changes in the DNA 
molecule arising from cylinder binding are clearly visible also from the agarose 
gel mobility shift assay. Consequently, as we see in the linear dichroism studies 
the M enantiomer has a greater effect on the DNA superhelical structure than 
the P enantiomer. This could also be attributed to the ability of the cylinder to fit 
into the groove and insert its chelates in between the stacked bases.  
 
The greater shape compatibility and thus the possible deeper groove 
penetration of the M enantiomer could also be extrapolated from fluorescence 
titration experiments. These indicated that the DNA provides better shielding 
from fluorescence quenching caused by water molecules to the M enantiomer. 
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In turn this could suggest that the P enantiomer is more freely bound to the 
DNA and this effect is reflected in the derived DNA affinities of the two 
enantiomers, which were found to be 3.10 ± 0.4 x 105 M-1 and 1.94 ± 0.5 x 105 
M-1 for M and P enantiomer respectively. The attained binding free energies for 
M and P enantiomers show that the M-[Ru2L3]4+-DNA adduct is more 
thermodynamically stable than P-[Ru2L3]4+-DNA complex, however formation of 
both complexes proceeds spontaneously under experimental conditions.  
In fact, both enantiomers induce a different level of structural changes in the 
biomolecule and therefore the magnitude of the free energy associated with 
these events should be different in both cases. However, distinctive fit of the 
cylinders to the major groove or alternatively recognition of two different DNA 
units by M- and P-[Ru2L3]4+, would give rise to distinct reorganisation of water 
molecules in DNA and/or to different DNA hydration levels in both cases. This 
might also have its effect on the structural changes in the DNA and 
consequently affect the energetics and stabilities of the systems. Furthermore, 
the molecular recognition event is also associated with the energy penalties 
resulting from the losses in translational and rotational degrees of freedom of 
the two interacting molecules and this can also be different in the two studied 
cases.  
The DNA recognition process by chiral triple-stranded helicates is a 
complex phenomenon and multiple factors need to be considered when 
discussing the binding features of the optical isomers and the outcomes of their 
complexation with DNA. For example, the structural changes that the 
enantiomers induce in the DNA structure might be associated not only with 
accommodation of the cylinder within the helix, which is attributed to molecular 
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symmetry properties of the interacting molecules but also with other factors like 
hydration levels, inter- and intramolecular interactions etc.. Indeed, all these 
events are related to the specific energy gains and losses and these are directly 
reflected in the thermodynamic profiles of the drug-DNA binding and the 
stabilities of the systems.  
As anticipated, the metal ion in the helicate does not seem to play a significant 
role in the recognition of DNA structures. The binding characteristics of the M 
and P enantiomers of ruthenium helicates, their effects on DNA coiling and 
degree of unwinding of the superhelical structures are highly comparable to 
these obtained for the iron analogues. Each of the two, [Fe2L3]4+ and [Ru2L3]4+, 
have the same ionic charge and very similar structural features.  
 
Understanding the molecular recognition in biological systems at the 
structural and thermodynamic level can be of prime importance for a rational 
drug design. Indeed chiral molecules can play a specific role in the 
understanding of the forces that drive the recognition processes. In this respect 
supramolecular cylinders, due to their unique symmetry properties, can be great 
models for better understanding of the major groove DNA recognition 
processes and, in the long term, for the design of sequence specific DNA 
binding drugs that target the DNA in a protein-like manner.  
In this context, the exhaustive studies on the interaction of both M and P 
enantiomers with DNA should be undertaken as a future work. This could 
include the determination of the thermodynamic profiles of both systems in 
order to better understand the forces and the magnitude of the energy 
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components that are involved in the recognition process and the DNA-cylinder 
molecular complex formation.  
Since both compounds have a potential as therapeutic agents against cancer, 
further detailed cytotoxicity testing on various different cancer cell lines should 
also be performed.  
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4 
The Enantiodifferentiation of Chiral 
Ruthenium(II) Triple-Stranded Helicates by 
Δ-TRISPHAT 
 
 
 
 
Abstract 
The interaction of Δ-TRISPHAT with a racemic mixture and two enantiopure Ru(II) triple-
stranded helicates, M(ΛΛ)- and P(ΔΔ)-enantiomer, have been investigated by 1H NMR. The 
proton spectra of the Ru compounds in the presence of the chiral shift reagent indicate that      
∆-TRISPHAT induces the NMR enantiodifferentiation of the two diastereomers by interacting 
with both isomers independently and appears to show chiral discrimination towards the 
interaction site. It is proposed that the Δ-TRISPHAT interacts with the ΛΛ–enantiomer along the 
C2 axis, having an effect mainly on the phenyl rings and methylene group in the central part of 
the helicate whereas with the ΔΔ – isomer it interacts along the C3 axis of the complex, thus 
affecting exclusively the pyridine protons.   
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4.1 Introduction  
Chiral molecular recognition has been of great interest in asymmetric 
chemistry, because of its considerable potential in bio- and nanotechnology, but 
also in pharmaceutical science and drug discovery. Indeed selective chiral 
discrimination and diastereoselective ion pairing phenomenon can be a 
valuable tool for supramolecular stereocontrol, diastereoselective synthesis and 
catalysis but also for development of resolving agents and NMR chiral solvating 
agents.[1] Particularly successful in these fields have been chiral 
hexacoordinated phosphates,[1-7] a representative example being the               
Δ-tris(tetrachloro-1,2-benzenediolato)phosphate(V) ion, commonly known as 
TRISPHAT (Fig. 4.1). TRISPHAT is an anionic coordination complex, where 
three bidentate tetrachlorocatecholate ligands are coordinated to a phosphorus 
atom. The compound exists in two isomeric forms: left-handed, Λ enantiomer 
and right-handed, Δ enantiomer and, importantly, both stereoisomers were 
found to be configurationally stable in solution. 
 
Fig. 4.1 Structure of [Tetrabutylammonium] [Δ-tris(tetrachloro-1,2-
benzenediolato)phosphate(V)]. 
 
TRISPHAT has been found to be especially useful as a chiral recognition agent 
for cationic molecules. Unlike other chiral shift reagents such as lanthanide-
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based [Eu(fod)3] or neutral (R)-α-methoxy-α-trifluoromethylphenylacetic acid, 
also known as Mosher’s acid (Fig. 4.2), TRISPHAT being an anionic species 
means it can act as a counterion for cationic molecules and thereby distinguish 
the two diastereomers by chiral ion pairing.[4] 
 
 
 
Fig. 4.2 Molecular structures of chiral shift reagents: (left) Eufod, (right) Mosher’s acid  
 
 
 
Consequently, it can be successfully used as a chiral resolving agent for mono- 
or dinuclear metal complexes.[5, 8] Lacour and co-workers used TRISPHAT as a 
diastereomeric resolving agent for dinuclear triple-stranded helicate systems by 
asymmetric extraction.[9] A similar approach was also applied by Raymond, 
where, by using a chiral cation (S)-N-Methylnicotinium (Fig. 4.3), it was possible 
to separate M and P enantiomers of anionic gallium dinuclear triple-stranded 
helicate.[10] 
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Fig. 4.3 Chiral cationic resolving agent, (S)-N-Methylnicotinium 
 
 
It was shown that TRISPHAT can also act as a NMR chiral shift reagent[11] and 
therefore it can be successfully used to determine the enantiopurity of the 
optical isomers, being more efficient in enantiodifferentiation than commonly 
used lanthanide shift reagent.[12] 
 
Previous studies on the interaction of TRISPHAT with an iron(II) triple-helicate 
carried out in Hannon group by C. R. Pearmund showed that in the presence of 
chiral TRISPHAT anion the splitting of some proton signals in the NMR 
spectrum of the Fe(II) cylinder occurs. This implies that the anion induces 
enantiodifferentiation of the two isomers present in the solution.[13]  
 
To examine the binding properties of the TRISPHAT and M and P enantiomers 
and possibly explore their interaction site(s) and to assess the enantiopurity of 
the complexes, NMR studies of the interaction between the racemic mixture, M 
and P isomer of the ruthenium triple-stranded helicate and Δ-TRISPHAT have 
been undertaken.  
Since the improved methodologies for the synthesis and purification and also 
enantiomer resolution of the Ru cylinder with ligand L (Fig. 4.4) have been 
successfully developed (See Chapter 2 and 3) and the enantiomers were found 
N +
H
N
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to be configurationally stable, this cylinder was chosen as a model compound 
for our systems.  
 
 
Fig. 4.4 Bispyridylimine ligand L 
 
4.2 Results and discussion 
As described in previous chapters the supramolecular Ru(II) triple-
stranded helicate is assembled from three symmetrical bis(bidentate) ligands 
(L), which are wrapped around two metal centers, aligned along the C3 axis of 
the complex. The compound exhibits a very high degree of symmetry and thus 
1H NMR spectrum shows 8 signals at room temperature. The 1H NMR spectrum 
of the hexafluorophosphate salt of racemic mixture, [Ru2L3](PF6)4, in CD3CN is 
shown in Fig. 4.5. 
  
 
 
Fig. 4.5 1H NMR spectrum of [Ru2L3](PF6)4 in CD3CN 
N N
N N
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The resonance that corresponds to the imine proton is the most shifted and 
appears at 8.71 ppm. Next we observe four signals coming from the pyridine 
ring protons, which appear at 8.45 (H3), 8.29 (H4), 7.72 (H5) and 7.65 ppm (H6).  
The two resonances corresponding to the phenyl protons in the centre of the 
molecule are visible in the spectrum as two doublets at the highest field of the 
aromatic region and appear at 6.96 and 5.71 ppm. There is one aliphatic signal 
in the spectrum, a singlet at 4.04 ppm, and it belongs to the methylene protons 
at the centre of symmetry of the ligand.  
To investigate the interactions of our helicate with the chiral TRISPHAT the 
conditions reported in earlier work from our group were used.[13] Four 
equivalents of [n-Bu4N][Δ-TRISPHAT] were added to a solution of [Ru2L3](PF6)4 
in CD3CN and the 1H NMR spectrum recorded. At this ratio no precipitation 
occurred but dramatic changes in the spectrum were observed.  
 
Fig. 4.6 Aromatic region of 1H NMR spectra of a) rac-[Ru2L3](PF6)4, b-d) [Ru2L3](PF6)4 with        
Δ-TRISPHAT 1:4, b) rac, c) M, d) P. 
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The resonance corresponding to the imine proton is the only one that remains 
undisturbed when TRISPHAT is added, while the other 7 resonances are 
strongly influenced by the chiral reagent (shifted and/or split) (Fig. 4.6b). The 
most visible and remarkable change that appears in the spectrum is the splitting 
of the signal coming from the aliphatic proton into two resonances. The two 
signals now appear at 3.94 and 4.02 ppm. The induced splitting of the 
resonances is also clearly visible in the phenyl region of the spectrum. The 
resonances, which previously appeared as doublets, now became doublets of 
doublets. It now becomes apparent that in the 3.90-7.10 ppm region the 
appearance of second set of signals has been induced, where, as described by 
Pearmund,[13] one set of resonances remains in the position of the native 
signals, before adding the shift reagent, and the second set of signals appears 
to be shifted towards higher field.  
In the pyridine region the changes in the spectrum are also significant. It is clear 
that the H6 and H5 resonances, which previously appeared on the spectrum as 
doublet and triplet, split and now become a combined multiplet with a center at 
7.71 ppm. Furthermore, the signal corresponding to H3 has transformed from a 
doublet to a doublet of doublets and the triplet coming from H4 has now become 
a multiplet. 
The observed changes in the spectrum of the racemic mixture of triple helicate 
upon addition of Δ-TRISPHAT indicate that the system now experiences an 
asymmetric environment, which is caused by enantiodifferentiation of the two 
optical isomers present in solution by the chiral agent. 
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TRISPHAT has been shown to interact dissimilarly with the two optical isomers 
of triple-helicates.[9] Therefore, to explore the interaction of TRISPHAT with the 
two enantiomers of the studied system, and possibly determining their 
interaction site(s) preferences, the experiment, which was performed for the 
racemic mixture, under the same conditions was undertaken for the 
enantiopure, configurationally stable isomers (for enantiomer separation see 
Chapter 3). 
The 1H NMR of both M and P enantiomers are identical and are consistent with 
the NMR spectrum of the racemic mixture. However, when Δ-TRISPHAT was 
added (four equivalents as for racemic mixture) the two systems became non-
equivalent. 
 
 
 
Fig. 4.7 Aliphatic region of 1H NMR spectra of a) rac-[Ru2L3](PF6)4, b-d) [Ru2L3](PF6)4 with Δ-
TRISPHAT 1:4, b) rac, c) M, d) P. 
 
 
In the 1H NMR spectrum of the M enantiomer, a 0.08 ppm upfield shift of the 
resonance corresponding to the aliphatic proton is observed compared to the 
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original spectrum (Fig. 4.7). The phenyl resonances are also shifted towards 
higher field, but there are no significant changes in the spectrum in the pyridine 
region apart from a small downfield shift of the H3 and H4 resonances. 
The spectrum of the P enantiomer in the presence of Δ-TRISPHAT also differs 
from the one before adding the chiral agent. However, in this case the most 
influenced resonances seem to be the ones situated at the periphery of the 
cylinder. H6 and H5 are now becoming more equivalent and appear on the 
spectrum as one multiplet, while the other pyridine protons do not seem to be 
significantly affected by the Δ-TRISPHAT. Unlike in the case of the M 
enantiomer, the signals corresponding to the central part of the helicate, 
methylene and phenyl protons remain essentially unchanged, thus the 
environment in this part of the right-handed helicate must be not affected 
(undisturbed) by the presence of the chiral shift reagent. This gives a key 
indication about the interaction site(s) between the optically active helicates and 
chiral hexacoordinated phosphate.  
It is clear that Δ-TRISPHAT induces the NMR enantiodifferentiation of the M 
and P enantiomer by interacting with the two isomers independently and 
showing chiral discrimination towards the interaction site. The two chiral 
molecules, or their ‘active moieties’, interact with each other via geometrical 
complementarities. Therefore, it can be proposed that the Δ-TRISPHAT 
recognises primarily the central part of the left-handed helicate (M), possibly by 
interacting with the phenyl rings along the C2 axis of the cylinder. 
The opposite effect is present in the case of the P helicate, where the electronic 
environment of central part of the complex seems to be undisturbed by 
presence of Δ-TRISPHAT while the terminal protons seem to be affected the 
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most. In this case the two molecules might ‘communicate’ with each other along 
the C3 axis of the long molecule, probably with phosphate atom pointing at the 
metal center, which may also be assisted by π-π stacking or edge to face 
interactions between the pyridine rings of the helicate and phenyl rings of        
Δ-TRISPHAT. This kind of interaction can be an effect of the structural 
preferences but ultimately a consequence of the homochiral ion pairing. A 
similar mode of recognition was also proposed by Correia et al. for the chiral 
mononuclear polypyridyl Ru(II) complexes.[14]  
 
 
 
 
4.3 General discussion, conclusions and further work 
 
Chiral molecular recognition is predominantly based on the molecular 
symmetry features of the two interacting species. This in turn is closely 
associated with the stereoselective intermolecular interactions and 
consequently with energy gains and losses while driving the system to the most 
thermodynamically stable state.  
The NMR studies presented in this chapter have shown that                   
Δ-TRISPHAT recognizes both optical isomers of the ruthenium triple-stranded 
helicate. Indeed, it appears that the TRISPHAT interacts independently with 
both enantiomers, however the recognition processes seem to be controlled by 
the stereochemical compatibility of the two interacting molecules leading to 
chiral discrimination between the interaction sites. 
There are two elements that are anticipated to drive the molecular recognition 
between the TRISPHAT and optical isomers of the [Ru2L3]4+: hydrophobic 
effects and electrostatic attractions. These interactions are expected to be the 
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dominant factors affecting the binding energetics of both M and P enantiomers 
to an approximately equal extent. Nevertheless the thermodynamics of the two 
discussed cases can be strongly differentiated by other elements of molecular 
recognition, which, in structural terms, could arise from the symmetry properties 
of the two interacting species.  
The 1H NMR spectra of the two enantiomers in the presence of Δ-TRISPHAT 
display distinctive shielding and deshielding effects suggesting that the different 
functional units of the M and P enantiomers are involved in the interactions with 
the hexacoordinated phosphate anion. The interaction of Δ-TRISPHAT with the 
M enantiomer results in more shielding of the phenyl and aliphatic protons of 
the cylinder and thus in lower values of δ. This could be consistent with π-π 
stacking of the two phenyl rings of the TRISPHAT molecule with the central 
phenyl rings of the left-handed helicate. Furthermore, this would give an 
additional energy gain to the system arising from the π-π interactions of the 
aromatic rings. However, in the case of the right handed, P enantiomer the 
same kind of interactions would be expected to be sterically hindered and 
hence less favorable. Indeed the NMR spectrum of the P enantiomer with       
Δ-TRISPHAT shows the central protons to be unaffected by the presence of 
TRISPHAT while the protons at the edges of the helicate i.e. pyridine protons, 
seem to be influenced. The high symmetry of the system suggests that the 
chiral hexacoordinated phosphate anion approaches the P helicate from the 
ruthenium site(s) along the C3 axes. This homochiral ion pairing, with the 
phosphorus atoms pointing at the ruthenium centers, would be expected to give 
rise to greater association of TRISPHAT moieties with the helicate units 
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allowing intermolecular interactions, which in turn would result in additional 
energy gain to the system.  
The different recognition sites of the M and P enantiomer could also lead to 
different level of loss in translational and rotational degrees of freedom and 
such factors would need to be taken into consideration while exploring the 
energetics of the M and P systems with TRISPHAT. Moreover, all the above 
factors would lead to certain energy benefits and penalties and this could be 
reflected in the distinctive binding affinities of Δ-TRISPHAT towards chiral 
helicates and consequently binding energetics.  
Although the NMR studies presented in this chapter do not give detailed 
information about the recognition event between the TRISPHAT and chiral 
helicates, and only a hypothesis about the binding sites can be drawn, the 
enantiodifferentiation of the M- and P-[Ru2L3]4+ by chiral hexacoordinated 
phosphate ions enables the enantiopurity of the dinuclear triple-stranded 
cylinders to be determined with greater precision than could previously be 
obtained. Indeed these NMR studies confirmed the efficiency of the 
methodology used for the separation of the optical isomers of the ruthenium 
triple-stranded helicates and can be successfully used to examine the purity of 
the enantiomeric complexes.  
 
Understanding the molecular insights of chiral recognition can have a 
great impact on development of new approaches for enantioselective synthesis 
or catalysis, host-guest chemistry, molecular aggregation, separation processes 
or drug design. In this context, the TRISPHAT – supramolecular chiral triple-
stranded helicate systems can serve as great model systems to study the 
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forces that drive this kind of molecular recognition hence to better understand 
the homo- and heterochiral ion pairing phenomenon. Therefore, comprehensive 
studies of the interactions of enantiomeric hexacoordinated phosphate ions with 
chiral triple-stranded helicates at the structural, kinetic and thermodynamic level 
should be a feature of further studies.  
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5 
Synthesis, Characterisation and DNA 
Binding Studies of 
Ru(II) Complexes With Ammine and 
Azopyridyl Building Units 
 
 
  
 
Abstract 
The DNA binding effects of di- and mononuclear Ru(II) complexes of the formula 
[Ru2L(NH3)8]Cl4 and [RuLazpy(NH3)4]Cl2, where L is the bisazopyridine ligand 
(C5H4N)N=N(C6H4)CH2(C6H4)N=N(C5H4N) and Lazpy is the azopyridine ligand 
(C5H4N)N=N(C6H5), have been investigated by UV-Vis spectroscopy, circular and linear 
dichroism and agarose gel electrophoretic mobility shift assays. Both complexes bind non-
covalently to ct-DNA inducing bending/coiling in the biomolecule. The binding of the dinuclear 
complex was found to be much stronger and appears to be more specific than the binding of the 
mononuclear complex.  Both complexes were found to have no antiproliferative effects in 
human cancer cell lines.  
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5.1 Introduction  
  Studies to probe the structural effects of a drug on biological systems and 
investigate the dependence of the structure of the ‘active’ moiety on its binding 
ability/properties have been a fast growing area of research in the past few 
decades. The effects of small molecules on DNA structures are of particular 
interest because of their potential to control or interfere with the processing of 
genetic information.  
  Polyamine species such as spermidine or spermine (Fig. 5.1) are often 
involved in regulation of cell proliferation and cell differentiation.[1]  
 
 
Fig. 5.1 Molecular structures of (left) spermidine, (right) spermine 
 
They neutralize the chromosomal DNA and protect it from damage by oxygen 
species.[2] As cationic molecules they bind to the DNA, acting either in the major 
or minor groove, and also induce structural changes in the biomolecule.[3] Some 
amine-based metal complexes can act as polyamine mimics, for example 
[Co(NH3)6]3+, which induces the structural transition of B- to Z- form of DNA.[4] 
Interestingly, this complex is more effective in stabilizing the Z-DNA structure 
than Na+ or Mg2+ ions.[5] Other analogues of this compound, such as the Ru 
analogue, are also able to induce DNA structural transitions, however, it was 
found that the Ru dication is less effective in stabilising the Z-DNA structure than 
H2N
H
N NH2
H2N NH
H
N NH2
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the parent Co(III) compound. The crystal structures of both complexes with 
oligonucleotides show that both ions particularly interact through hydrogen 
bonding with guanine residues (Fig. 5.2 ).[6] Such hydrogen-bonding is a feature 
of ammine based ligands. 
 
Fig. 5.2 The interaction of ion [Ru(NH3)6]2+ with Z-DNA; (left) spacefill representation, (right) 
hydrogen bonding between Ru cation and guanine residues (PDB ref. 2HTO).[6] 
 
In [Ru(NH3)4(diimine)]2+, where the bidentate diimine is a large, aromatic 
heterocyclic ligand suited to intercalation, the NH3 ligands also tend to be 
involved in hydrogen bonding with the intrastrand nucleobases assisting the 
intercalation of diimine between the bases.[7] These intercalating complexes 
also induce some DNA structural changes and were shown to cleave DNA.[8] 
When irradiated, NH3 ligands can act as photolabile species. Turro et al. 
showed that photolysis of cis-[Ru(bpy)2(NH3)2]2+ (bpy - 2,2′-bipyridine) in water 
led to the photoinduced loss of NH3 ligands and formation of a cationic aqua-
species, which could then coordinate to the bases of  ss- and/or ds-DNA.[9] This 
opens up the potential use of this class of compounds as therapeutic prodrugs 
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in the field of photodynamic therapy (PDT). A number of ammine compounds 
have been already explored in biological systems. For example, an ammine-rich 
mixed-valence oxygen-bridged trinuclear ruthenium compound, commonly 
known as ruthenium red (Fig. 5.3) was found to bind to calcium-binding proteins 
and particularly inhibit Ca2+ჼuptake by mitochondria.[10] 
 
 
Fig. 5.3 Molecular structure of ruthenium red 
 
Farrell and co-workers developed a series of polynuclear platinum ammine-
based complexes, which were found to bind along the DNA phosphate 
backbone[11] and also exhibit micromolar cytotoxicity against cancer cells.[12]  
Other ammine-based transition metal complexes such as mononuclear 
[Ru(NH3)4Cl2]Cl or [Ru(NH3)3Cl3] also show promising cytotoxic activity against 
tumours.[13, 14] This kind of complexes bind to histidine imidazoles in proteins such 
as albumin and transferrin, which have been suggested to mediate their uptake 
into cells.[15]  
An alternative promising class of potential anticancer drugs are azopyridyl metal 
complexes (See Chapter 1). Reedijk and co-workers reported isomers of 
[RuLazpy2Cl2] and showed that the σ- isomer of this compound shows remarkably 
higher cytotoxic activity against a range of tumour cell lines compared to its β- 
and γ-analogues.[16] More recently Hotze prepared a set of isomeric dinuclear  
Ru O Ru
NH3H3N
H3N
H3N NH3
O Ru
H3N NH3
H3N NH3
NH3H3N
H3N NH3
NH3
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bis-azopyridine cylindrical complexes, [Ru2L2Cl4], which exhibit up to 10 fold 
higher cytotoxic activities against tumour cells than cisplatin.[17]  
 Since cylinders have dramatic effects on DNA structure (coiling) and metal 
ammine complexes, also affect DNA structure (altering its conformation), and 
since both offer different types of non-covalent DNA recognition we decided to 
explore whether introducing both aspects within the same molecule might create 
species with unusual DNA binding. Creating such species involves replacing one 
or more strands of the cylinder with ammine groups (using single-stranded or 
double-stranded cylinders). To initiate this work we chose to investigate the 
dinuclear single stranded species since this avoids the isomers observed with the 
double-stranded helicates.[17] Alongside this, a mononuclear analogue was 
prepared to compare its properties. Herein we combine the bis-azopyridine 
approach with the ammine complex approach and present the DNA binding of 
the two Ru(II) mixed ammine- and azopyridine complexes. A symmetrical 
dinuclear ruthenium(II) complex with bisazopyridine bridging ligand (La) and 
ammine co-ligands and a mononuclear analogue of this compound with 
azopyridine ligand (Lazpy), (Fig. 5.4) are reported along with their action on the 
DNA structure and in cells. 
 
 
Fig. 5.4 a) bisazopyridine ligand, b) azopyridine ligand 
N
N
N
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These compounds are designed to have no or very little potential to bind 
coordinatively to the DNA or to intercalate between base pairs, but this leaves 
open the possibility of binding along the grooves and/or interacting with the 
phosphate backbone.  
 
5.2 Results and discussion 
5.2.1 Synthesis 
5.2.1.1 Synthesis and characterisation of [Ru2La(NH3)8]Cl4 
Ligand La (Fig. 5.5) was prepared from 2-nitrosopyridine and                          
4,4’-methylenedianiline according to the previously described method.[18, 19] 
 
 
Fig. 5.5 Chemical structure of bisazopyridine ligand La 
 
 
Ligand La was coordinated to the Ru(II) by stirring a solution of the ligand with 
[Ru(NH3)5(H2O)](PF6)2 in acetone under an argon atmosphere. The complex 
was purified by flash chromatography on a neutral alumina column to afford a 
pure compound in 62 % yield. The 1H NMR spectrum of the dinuclear complex 
shows one aliphatic signal corresponding to the bridging -CH2 group in the 
centre of the ligand and six aromatic proton signals, indicating the presence of 
single, symmetrical species in the solution (Fig. 5.6). 
 
 
N N
N N
N N
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Fig. 5.6 1H NMR spectrum of [Ru2La(NH3)8]Cl4 in MeOD 
 
 
The mass spectrum is dominated by peaks corresponding to [Ru2La(NH3)8]Cl3+ 
(m/z 250.1) [Ru2La(NH3)7]Cl3+, (m/z 245.2) [Ru2La(NH3)6]Cl3+, (m/z 239.1) 
[Ru2La(NH3)5]Cl3+, (m/z 233.3) and  [Ru2La(NH3)8]2+  (m/z 358.4). Elemental 
analysis data was consistent with a formulation of [Ru2La(NH3)8]Cl4. Red needle 
– shaped crystals suitable for X-ray analysis were obtained by slow diffusion of 
Et2O into a methanolic solution of the chloride salt of the compound. As 
expected, the crystal structure shows the cation to be a symmetrical dinuclear 
species where two octahedral Ru centers are linked by one bisazopyridine 
ligand, which separates the two Ru centers by 9.5 Å. There is no helical twist of 
the linking ligand about the Ru atoms and this results in orientation of all 
ammonia ligands to one side of the complex with the linking ligand acting as a 
bridge between the two metal centers (Fig. 5.7). Each Ru atom has also four 
coordinated ammonia ligands with Ru-N (NH3) distances of 2.11-2.16 Å. The 
central phenyl rings are twisted with respect to each other with an inter planar 
angle of 85o.  The phenyl rings are also twisted with respect to the neighbouring 
pyridine rings (torsion angles 52 and 44o). 
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Fig. 5.7 Crystal structure of the cation in [Ru2La(NH3)8]Cl4. Hydrogen atoms and counterion are 
omitted for clarity 
 
 
Fig. 5.8 shows the crystal packing diagram for [Ru2La(NH3)8]4+. The tetra-
cations are arranged in parallel chains, which are held together by hydrogen 
bonding. Each metal complex cation is engaged in hydrogen bonding between 
its ammine groups and Cl- counterions, which in turn are involved in hydrogen 
bonding with the two other neighbouring cations enabling the large highly 
organised scaffold to be formed.  
 
 
Fig. 5.8 Packing diagram for [Ru2La(NH3)4]4+ showing hydrogen bonding interaction between the 
ammine groups and chloride counterions (yellow). Hydrogen atoms and solvent molecules have 
been removed for clarity. 
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The [Ru2La(NH3)8]4+ was also crystallized as a hexafluorophosphate salt. The 
large red crystals were obtained by slow diffusion of acetonitrile from an 
acetonitrile/H2O solution of the compound. The complex crystallized in a 
monoclinic crystal system with the space group P2(1)/n. The crystal structure 
shows two crystallographically unique [Ru2La(NH3)8]4+ cations in the asymmetric 
unit cell (Fig. 5.9).  
 
Fig. 5.9 Crystal structure and specefill representation of cations in [Ru2La(NH3)8](PF6)4. 
Hydrogen atoms, counterions, and solvent molecules have been omitted for clarity.  
 
 
Differences between the two unique cations in the structure arise primarily from 
dissimilarity in the Ru···Ru distances in the two molecules (9.2 Å and 7.8 Å), 
which are smaller than in the previous structure. As seen in the structure of 
[Ru2La(NH3)8]Cl4, no helical twist of the linking ligand is observed in either 
molecule. 
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5.2.1.2 Synthesis and characterisation of [RuLa(NH3)4]Cl2 
One of the side products of the reaction towards the dinuclear single–
stranded compound, described above, was the mononuclear complex of 
formula [RuLa(NH3)4]Cl2. The equilibrium of the reaction towards this compound 
was changed by increasing the molar ratios of the reagents (1: 1). Reaction of L 
with [Ru(NH3)5(H2O)](PF6)2 was carried out in acetone under argon 
atmosphere.  Purification of the product by column chromatography afforded 
the pure compound in 55 % yield. Under all conditions explored both, 
mononuclear and dinuclear species formation was observed.  
The [RuLa(NH3)4]4+ is not symmetrical due to the coordination of the Ru atom 
only on one site of the bis-bidentate ligand and that results in the appearance of 
two sets of peaks in the 1H NMR spectrum (Fig. 5.10). Assignment of the peaks 
was performed on the basis of 2D NMR experiments (see Supplementary 
information). 
 
 
Fig. 5.10 1H NMR spectrum of [RuLa(NH3)4]Cl2 in MeOD 
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X-ray quality crystals were obtained by slow diffusion of benzene into an 
acetonitrile solution of its hexafluorophosphate salt of the compound. The 
crystal structure shows four ammonia ligands and one azopyridine ligand 
coordinated to one Ru atom (Fig. 5.11) with Ru-N (NH3) distances 2.14 - 2.17 Å.  
 
 
Fig. 5.11 Crystal structure and spacefill representation of cation in [RuLa(NH3)4](PF6)2. 
Hydrogen atoms, counterions and solvent molecules have been omitted for clarity.  
 
 
The ligand is bent about the central CH2 group by 75.24o and it adopts the trans 
configurations of the phenyl and pyridine rings about the central N-N bonds on 
both sites. In the ‘free’, uncoordinated, part of the ligand the phenyl and pyridine 
rings are in the same plane, while the coordination of the Ru atom causes the 
twist of the pyridine and phenyl ring planes by 58o. Unlike in the dinuclear 
complex, here the ruthenium atom with four coordinated ammonia ligands is 
pointing away from the rest of the ligand.  
Analysis of the crystal packing (Fig. 5.12) reveals that the metal complex 
cations are aligned in chains through π-π stacking between the phenyl rings of 
alternating complexes. The inter-planar distance between the adjacent phenyl 
rings is ~ 3.6 Å. Each chain aligns with two other chains in head-to-head or tail-
to-tail fashion.   
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Fig. 5.12 Crystal packing diagram for [RuLa(NH3)4]2+ showing the π-π stacking interactions 
between phenyl rings. Hydrogen atoms, counterions and solvent molecules have been removed 
for clarity.  
 
 
The [RuLa(NH3)4]Cl2 was found to be unstable in solution. Upon standing 
in methanolic or aqueous solution a change in the colour of the solution from 
orange to deep red/purple was observed. Given that the mass spectral data 
indicated the presence of species of a formulation [RuLa(NH3)4]2+ and 
[Ru2La2(NH3)4]4+ and NMR data demonstrated the presence of numerous 
entities that could be assigned to several different isomers of dinuclear 
product(s), it would appear that the complex [RuLa(NH3)4]Cl2 undergoes 
dimerisation under these conditions and for this reason, further biological 
studies with this compound have not been undertaken.  
 
5.2.1.3 Synthesis and characterisation of [RuLazpy(NH3)4]Cl2 
The literature procedure for the synthesis of ligand Lazpy (Fig. 5.13) 
involves a condensation reaction between 2-aminopyridine and nitrosobenzene 
and further purification by recrystallization from petroleum ether.[20, 21]  
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Fig. 5.13 Chemical structure of azopyridine ligand Lazpy  
 
 
In these studies the ligand was prepared by analogous procedures by instead 
reacting 2-nitrosopyridine and aniline in dichloromethane with one drop of 
glacial acetic acid. It was found that the compound could be successfully 
purified by silica gel column chromatography with chloroform as an eluent 
giving a yield of 74 %. The characterisation data was in agreement with that 
reported in the literature. 
Coordination of the ligand Lazpy to the ruthenium centre was performed by 
stirring [Ru(NH3)5(H2O)](PF6)2 and ligand Lazpy in acetone under an argon 
atmosphere. The precipitation of the product afforded a desired compound, 
[RuLazpy(NH3)4]Cl2, in 29 % yield. The 1H NMR spectrum of the compound 
reveals only one set of aromatic peaks suggesting that a single compound is 
formed (Fig. 5.14). 
 
Fig. 5.14 1H NMR spectrum of [RuLazpy(NH3)4]Cl2 in MeOD 
N
N
N
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The electrospray mass spectrometry analysis shows peaks corresponding to 
the cations [RuLazpy]Cl+ (m/z 320.1), [RuLazpy(NH3)2]Cl+ (m/z 354.1), 
[RuLazpy(NH3)3]Cl+ (m/z 371.1), [RuLazpy(NH3)4]Cl+ (m/z 388.2) and partial 
microanalytical data were consistent with the formulation [RuLazpy(NH3)4]Cl2.  
X-ray quality crystals of this compound were obtained by slow diffusion of 
benzene into an acetonitrile solution of the hexafluorophosphate salt of the 
complex. The compound crystallized in the monoclinic crystal system with the 
space group P2(1)/c. The structure contains two PF6- ions per ruthenium 
complex and a molecule of solvent benzene. The crystal structure of the cation 
shows one azopyridine ligand to be coordinated to the ruthenium atom, which 
has also coordinated four ammonia ligands (Fig. 5.15) with Ru-N distances of 
1.91 – 2.13 Å. In the azopyridine unit the phenyl and pyridine rings adopt a 
trans conformation about the central N=N bond. The torsion angle between 
N=N and phenyl ring is 50o. 
 
 
 
Fig. 5.15 Crystal structure and spacefill representation of [RuLazpy(NH3)4]Cl2. Hydrogen atoms 
and counterions are omitted for clarity. 
 
 
The analysis of crystal packing shows that the metal complex cations are 
aligned in chains (Fig. 5.16). The initial analysis shows that each cation 
interacts via hydrogen bonding with the neighbouring PF6- ion, which further 
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hydrogen bonds with another neighbouring [RuLazpy(NH3)4]4+. However, due to 
the high disorder of one of the PF6- ions in the structure further discussion 
cannot be undertaken.  
 
 
 
Fig. 5.16 Crystal packing of [RuLazpy(NH3)4]2+. Hydrogen atoms, counterions and solvent 
molecules have been omitted for clarity.  
 
 
 
5.2.2 Interaction with DNA 
Compound [Ru2La(NH3)8]Cl4 and [RuLazpy(NH3)4]Cl2 were selected for 
further studies. These complexes show the potential to bind to DNA through a 
range of non-covalent interactions: electrostatic interactions between cationic 
complex and polyanionic DNA, hydrophobic interactions within DNA grooves, 
hydrogen bonding of ammine ligands with phosphate backbone or within 
intrastrands guanine nucleobases and/or partial intercalation of the azopyridine 
ligand between the stacked bases. To probe the complexes interactions with 
DNA the absorption based spectroscopic techniques such as circular and linear 
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dichroism as well as agarose gel electrophoretic mobility shift assay and DNA 
thermal denaturation analysis were employed.  
 
5.2.2.1 Absorption spectral studies 
The UV-Vis absorption spectra of the two complexes selected for the 
DNA binding studies, [Ru2La(NH3)8]4+ and [RuLazpy(NH3)4]2+, reveal intense π-π* 
transition bands centered at ~225 nm and ~330 nm and, corresponding to the 
red/orange colour of the chromophore, broad metal to ligand charge transfer 
bands (MLCT) with the maximum at ~ 477 nm. 
 
 
 
Fig. 5.17 UV-Vis titration spectra of complex (50 µM, 20 mM NaCl, 1 mM sodium cacodylate) 
upon addition of DNA; (left) [Ru2La(NH3)8]Cl4, (right) [RuLazpy(NH3)4]Cl2. Mixing ratios are 
indicated as complex to DNA base.  
 
 
Upon addition of ct-DNA no significant changes in the MLCT regions of the 
compounds are observed indicating that the compounds are not altered upon 
binding to DNA (Fig. 5.17).  Moreover, a small hyperchromic effect in the MLCT 
band of [RuLazpy(NH3)4]Cl2 was observed upon addition of DNA, while 
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[Ru2La(NH3)8]Cl4 displayed first hyper-4 and then hypochromicity5 implying two 
DNA binding modes for this complex.  
 
5.2.2.2 Circular dichroism 
To further explore the possible effect of the compounds on the DNA 
structure CD titrations of the compounds into a solution of the ct-DNA (300 µM, 
20 mM NaCl, 1 mM sodium cacodylate) were performed.  
 
Upon addition of [Ru2La(NH3)8]Cl4 into DNA solution a strong induced CD signal 
in the in-ligand region of the compound is observed, clearly indicating binding of 
the compound to the DNA. The retained shape of the DNA CD bands below 
300 nm confirms that a B-DNA conformation is maintained throughout the 
titration (Fig. 5.18).  
The addition to DNA of the mononuclear analogue [RuLazpy(NH3)4]Cl2 causes 
less dramatic effects. Only very small changes in the DNA region are observed 
upon addition of the complex to the solution of DNA and no induced CD signal 
in the MLCT region of the complex is observed throughout the titration.   
 
 
 
 
 
 
                                                
4 hyperchromicity – increase of absorbance of a substance 
5 hypochromicity – decrease of absorbance of a substance 
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Fig. 5.18 CD spectra of DNA (300 µM, 20 mM NaCl, 1 mM sodium cacodyate) upon addition of: 
(top) [Ru2La(NH3)8]Cl4, (bottom) [RuLazpy(NH3)4]Cl2; (mixing ratios are indicated as DNA base to 
complex, 220-300 nm – 1 mm pathlength cuvette, 280-500 – 1 cm cuvette). 
 
 
5.2.2.3 Flow linear dichroism (LD)  
The linear dichroism titrations were conducted using the same conditions 
as used for CD experiments (300 µM ct-DNA, 20 mM NaCl, 1 mM sodium 
cacodylate). The LD spectra of ct-DNA alone and in the presence of different 
concentrations of Ru complexes are shown in Fig. 5.19. 
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Fig. 5.19 LD spectra of DNA (300 µM, 20 mM NaCl, 1 mM sodium cacodylate) upon addition of 
complex (top) [Ru2La(NH3)8]Cl4, bottom [RuLazpy(NH3)4]Cl2. Mixing ratios are indicated as DNA 
base to complex.  
 
 
Additions of the dinuclear complex to DNA solution gives rise to an induced LD 
signal in the 350 – 550 nm region. This indicates that the compound binds the 
DNA in a specific orientation(s). This effect is not observed for the mononuclear 
complex. However, in both cases a loss of the magnitude of the signal in the 
DNA region (260 nm) upon addition of the compound(s) is observed that 
indicates a loss in orientation of the DNA. This is consistent with coiling/bending 
of the biomolecule or an increase in its flexibility, but this effect is much weaker 
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for the mononuclear complex. Nevertheless, the loss of the signal (in the 
absence of DNA precipitation) is confirmation that the mononuclear compound 
does bind to the DNA.  The weaker effect could reflect a lower coiling/bending 
efficacy or the expected lower binding constant or both.  
 
5.2.2.4 DNA thermal denaturation 
DNA thermal denaturation experiments involve analysis of the DNA 
absorption under heating and cooling conditions. When the temperature 
increases the hydrogen bonding between the strands is interrupted, base-
stacking is lost and consequently DNA strands become separated. This results 
in the hyperchromic effect, where the UV absorption of the DNA increases and 
this can be monitored by UV-Vis spectroscopy. The melting temperature, the 
Tm, is the midpoint at which half of the DNA is denatured into single strands and 
half remains in a double helical state (Fig. 5.20). 
 
 
 
 
Fig. 5.20 Thermal denaturation profile of ct-DNA (20 mM NaCl, 1 mM sodium cacodylate). 
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When the small molecule binds to the DNA the strand separation is often 
reduced and the DNA duplex stabilised. This in turn gives rise to higher DNA 
melting temperatures.  
  
The effect of temperature on the stability of the ct-DNA-compound complex was 
investigated. The profiles of thermal denaturation of DNA in the presence and 
absence of the compounds show that the interacting drugs stabilize the duplex 
DNA. The stabilization effect(s) seems to be much stronger for the dinuclear 
complex compared to the mononuclear analogue. On addition of 
[Ru2La(NH3)8]Cl4 to a ct-DNA solution (100 µM, 20 mM NaCl, 1 mM sodium 
cacodylate) the DNA melting temperature (Tm) was found to increase from 2oC 
at the ratio 40 : 1 (DNA base: complex) to 7oC at the ratio 5 : 1.  However, a 
much weaker stabilization effect was observed for the mononuclear 
[RuLazpy(NH3)4]Cl2, where the Tm changes were smaller than 1oC even at the 
highest used ratio 5 : 1 (DNA base : complex) (Table 5.1). 
 
 
ΔTm (oC) Complex concentration 
(µM) [Ru2La(NH3)8]Cl4 [RuLazpy(NH3)4]Cl2 
2.5 2 <1 
5 4 <1 
10 6 <1 
20 7 <1 
 
Table 5.1 ΔTm of ct-DNA in the presence of Ru(II) complexes 
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5.2.2.5 Agarose gel electrophoretic mobility shift assay 
To explore whether the compounds can interfere with the DNA 
supercoiling, agarose gel electrophoresis experiments with negatively 
supercoiled DNA were performed. Fig. 5.21 displays electrophoresis gels in 
which a mixture of relaxed and negatively supercoiled pBR322 plasmid DNA 
was treated with increasing amounts of ruthenium complexes (left to right). 
However, in both cases no unwinding of supercoiled DNA was observed in the 
tested range of concentrations.  
 
Fig. 5.21 Agarose gel electrophoresis of circular plasmid pBR322 after 30 min of incubation with 
increased amount of complex a) [Ru2La(NH3)8]Cl4, lanes 1-8, rb = 0.033, 0.05, 0.063, 0.083, 0.1, 
0.125, 0.167, 0.25;  b) [RuLazpy(NH3)4]Cl2, lanes 1-9, rb = 0.025, 0.033, 0.05, 0.063, 0.083, 0.1, 
0.125, 0.167, 0.25;  C-control,  sc – supercoiled DNA, oc – open circular DNA. 
 
 
5.2.3 Cell tests 
Both complexes were also investigated for their antiproliferative 
properties in human cancer cell lines. Compounds were tested in vitro in breast 
cancer cells (MDA-MB-231, T47-D) using cell viability assay (MTT). However, 
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the initial studies of the cytotoxicity of both compounds indicated that the 
compounds were not active against tested cell lines (IC50 > 100). 
 
5.3 General discussion, conclusions and further work  
The above DNA binding studies of Ru-NH3 complexes show that both 
compounds interact with DNA. However, [Ru2La(NH3)8]4+ shows a greater 
binding effect than its mononuclear analogue. This can be a consequence of a 
number of factors. The larger hydrophobic surface and the higher charge of the 
dinuclear complex has presumably considerable impact on the strength of the 
attractive forces between the complex and DNA and thus might be determining 
the binding affinity of the drug towards biomolecule. Nevertheless, the greater 
amount of ammonia ligands can also contribute to the overall binding affinity of 
the complex by direct hydrogen bonding with bases and/or the phosphate 
backbone. The size and shape of the binding molecule probably also can play a 
significant role in the recognition process. 
 
In conclusion, three new ruthenium complexes based on ammine and 
azopyridine moieties have been prepared and characterised. The binding 
studies of the [Ru2La(NH3)8]4+ and [RuLazpy(NH3)4]2+ showed that the dinuclear, 
higher charged compound has a greater effect on the DNA structure than its 
mononuclear analogue. Both complexes interact with DNA causing 
coiling/bending of the biomolecule and stabilize the duplex DNA at high 
temperatures while the structures of the complexes themselves seem to be 
unaltered upon interaction.  However, the effects on DNA structure are less 
than those of the literature ammine complexes and cylinders indicating that, at 
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least within these compounds studied herein, a combination of their two 
individual effects is not achieved. Consistent with this, neither compound was 
active in breast cancer cell lines. 
Therefore, the work indicates that retaining the multistrand cylinder shape is 
crucial for the cylinder-like activity and that also the presence of an intercalator 
is important in the activity of metal-mixed ammine diimine complexes.  
 
Further work on these systems should include testing the above 
compounds for their photoactive properties. Following this approach, the 
dinuclear double stranded compounds with azopyridine linking ligands and 
ammine co-ligands should be prepared and tested for their biomolecule binding 
properties and activities in cancer cells. 
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6.1 General 
All starting materials were purchased from Sigma Aldrich, Fluorochem or Acros 
Organics and used without further purification. NMR spectra were recorded on 
a Bruker AVIII300, AVIII400 or AV500 NMR spectrometer. UV-Vis spectra were 
recorded on a Cary 5000 Varian spectrophotometer using quartz cuvettes and 
far UV grade solvents. Fluorescence spectra were obtained using Shimadzu 
RF-5301 PC spectrofluorimeter. Electrospray Ionisation (ES) and High 
Resolution MS (HRMS) analyses were performed on a Micromass LCT Time of 
Flight mass spectrometer in positive ionisation mode. Microanalyses were 
carried out on a Leeman Labs CE44 CHN analyser. Infrared spectra were 
recorded using a Perkin Elmer Spectrum 100 FTIR spectrometer as neat films.  
 
6.2 Syntheses 
6.2.1 Synthesis of cis-[Ru(DMSO)4Cl2] 
The compound was prepared by slight modification of a procedure described by 
Evans et al. [1] 
RuCl3 · xH2O (1.1 g) was added to DMSO (10 mL) and the mixture was heated 
to reflux and then maintained at reflux for 5 min. The dark brown solution was 
allowed to stand and cooled to room temperature, when acetone (10 mL) was 
added and the mixture was left overnight in an open beaker in the fume 
cupboard at room temperature. The yellow hexagonal crystals that formed  
were filtered off, washed with ice-cold acetone, diethyl ether and dried in vacuo. 
Yield (1.2 g, 59 % for x=3)  
EA (%): Found: C: 20.1, H: 4.9; Calc. for Ru(C2H6SO)4Cl2: C: 19.8, H: 5.0 
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IR, ν (cm-1):  3008 (w), 1603 (m), 1525 (m), 1441 (m), 1340 (m), 1305 (m), 1209 
(w), 1112 (s), 1084 (s), 1018 (s), 991 (s), 961 (s), 931 (s), 843 (m), 791 (m), 717 
(m), 675 (s). 
 
 
6.2.2 Synthesis of L 
 
 
The compound was prepared as described by Painting.[2, 3] 
Pyridine-2-carboxaldehyde (0.214 g, 2.0 mmol) and 4,4’-methylenedianiline 
(0.198 g, 1.0 mmol) were stirred in ethanol (50 mL) at room temperature for 4h. 
The resulting white-cream precipitate was collected by vacuum filtration, 
washed with ethanol (20 mL) and dried in vacuo. Yield (0.31 g, 82 %) 
1H NMR (400MHz, CDCl3) δ = 8.71 (ddd, J = 4.8, 1.6, 0.9 Hz, 1H, H6), 8.63 (s, 
1H, H7), 8.20 (d, J = 7.9 Hz, 1H, H3), 7.79 (td, J = 7.7, 1.5 Hz, 1H, H4), 7.35 
(ddd, J = 7.5, 4.8, 1.2 Hz, 1H, H5), 7.27 (s, 4H, H9/10), 4.04 (s, 1H, H12) 
13C NMR (400 MHz, CDCl3) δ = 160.05 (C7), 154.69 (C2), 149.7 (C6), 149.05 
(C8), 139.76 (C11), 136.63 (C4), 129.7 (C9/10), 125.04 (C5), 121.86 (C3), 121.41 
(C9/10), 41.08 (C12) 
MS (ES+, CHCl3) m/z = 399.1 [M + Na]+ 
EA (%): Found: C: 80.0, H: 5.3, N: 14.9; Calc. for C25H20N4: C: 79.8, H: 5.4,      
N: 14.9.  
N N
N N
C25H20N4
FW: 376.5
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IR, ν (cm-1):  3062 (w), 1625 (m), 1581 (m), 1566 (m), 1503 (m), 1466 (m), 1433 
(s), 1348 (w), 1198 (w), 1147 (m), 1089 (w), 990 (m), 881 (m), 827 (s), 817 (s), 
741 (s), 783 (s), 651 (m), 616 (s), 578 (s). 
 
 
6.2.3 Synthesis of [Ru2L3]Cl4 
 
The compound was prepared and purified by modification of the literature 
procedure described by G. Pascu et al. [4] 
Method 1 
cis-[Ru(DMSO)4Cl2] (0.242 g, 0.50 mmol) and ligand L (0.282 g, 0.75 mmol) in 
ethylene glycol (35 mL) in a 50 mL Schlenk flask were placed in a preheated 
200oC oil bath and the reaction mixture was stirred at reflux under argon 
atmosphere for 6 days when a dark orange solution was formed. The solution 
was cooled down to room temperature and a saturated aqueous solution of 
NH4PF6 (10 mL) was added. The dark brown precipitate that formed was filtered 
off, washed with water (200 mL) and vacuum dried. The precipitate was 
dissolved in CH3CN (20 mL) and diethyl ether (150 mL) was added. The 
precipitate was filtered off, washed with water and diethyl ether and dried in 
vacuum. The crude was purified by column chromatography using silica gel and 
5-15 mM NH4PF6 in CH3CN/H2O (3:1). The compound was eluted as a second 
intensive orange band following the small pink/orange band, which was 
discarded. The corresponding chloride salt of the complex was obtained by 
anion metathesis with n-tetrabutylammonium chloride. Yield (41 mg, 11 %) 
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An alternative method of purification involved the positive ion exchange 
chromatography on the Sephadex C-50 (Sigma Aldrich). 
Sephadex was swell overnight in H2O and then packed onto a column to form a 
surface of 25 mm/250 mm. Crude compound was dissolved in H2O and ten 
loaded onto a column. Once the solution was loaded, the column was washed 
with H2O until no more colour was observed and then washed/eluted with 
aqueous solutions of NaCl (0.05, 0.1, 0.4, 0.4, 0.8 M). The pure compound was 
eluted with 0.4 M aq. NaCl and further desalted using C-18 Sep-Pak cartridges 
(Waters). Yield (59 mg, 16 %) 
1H NMR (400 MHz, MeOD) δ  = 9.00 (s, 1H, H7), 8.60 (d, J = 7.4, 1H, H3), 8.41 
(td, J = 7.7, 1.5, 1H, H4), 7.90 - 7.78 (m, 2H, H5&6), 7.08 (d, J = 7.3, 2H, HPh), 
5.79 (d, J = 8.5, 2H, HPh), 4.09 (s, 1H, H12) 
13C NMR (400 MHz, MeOD) δ = 171.9 (C7), 158.1 (C2/8), 153.9 (C6), 150.4 
(C2/8), 143.0 (C11), 140.2 (C4), 132.3 (C3), 131.4 (CPh), 131.2 (C5), 122.5 (CPh), 
40.6 (C12) 
MS (ES+, MeOH) m/z = 333.1 [Ru2L3]4+, 444.0 [Ru2L3]3+, 683.7 [Ru2L3]Cl2+, 
701.2 [Ru2L3]Cl22+ 
EA (%): Found: C: 46.4, H: 3.2, N: 8.7, Calc. for Ru2C75H60N12P4F24(H2O):        
C: 46.7, H: 3.2, N: 8.7 
EA (%): Found: C: 61.4, H: 4.1, N: 11.3, Calc. for Ru2C75H60N12Cl4: C: 61.1,     
H: 4.1, N: 11.4 
IR, ν (cm-1): 2960 (m), 1608 (w), 1550 (w), 1501 (m), 1469 (m), 1437 (m), 1254 
(w), 1206 (m), 1109 (w), 1017 (w), 865 (w), 817 (w), 781 (s), 748 (s), 654 (s)  
Crystal structure data for C75H60N12Ru2, 4Cl, 6(H2O), M = 1581.39, Cubic, a = 
25.7546(5) Å, b = 25.7546(5) Å, c = 25.7546(5) Å, β = 90°, U = 17083.0(6) Å3, T 
= 120 (2) K, space group I213, Z = 8, 22771 reflections measured, 5010 unique 
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(Rint = 0.0453) which were used in all calculations. Final R-indices (I>2σ(I)): R1 
= 0.0752, wR2 = 0.2241. 
 
Method 2 
cis-[Ru(DMSO)4Cl2] (0.242 g, 0.50 mmol) and ligand L (0.282 g, 0.75 mmol) in 
ethylene glycol (35 mL) were placed in a microwaveable sealed vessel and 
reacted using microwave energy during 3-4 1h long cycles at 180oC (60% of 
400W in pressure vessel). The solution was cooled down to room temperature 
and a saturated aqueous solution of NH4PF6 (20 mL) was added. The dark 
brown precipitate that formed was filtered off, washed with water (200 mL) and 
vacuum dried. The precipitate was dissolved in a minimum amount of CH3CN 
(10 mL) and the crude was re-precipitated with diethyl ether (100 mL). The 
precipitate was filtered off, washed with diethyl ether and dried in vacuo. The 
crude was purified by column chromatography on a silica gel stationary phase 
and 5-15 mmol solution of NH4PF6 in CH3CN/H2O (3:1) as an eluent. The 
compound was eluted as a second intensive orange band. The corresponding 
chloride salt of the complex was obtained by anion metathesis with n-Bu4NCl. 
Yield (45 mg, 12 %) 
 
6.2.3.1 Separation of optical isomers of [Ru2L3]Cl4  
Cellulose (~ 20 µm, Sigma Aldrich) was mixed with 0.2 M aq. solution of NaCl to 
form a slurry. The packing was performed by pouring the slurry onto a column 
(19 x 250 mm) and applying pressure from a peristaltic pump. A total column 
length of  ~ 200 mm was prepared and the excess solvent was eluted.  
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The analytically pure racemic mixture of [Ru2L3]Cl4 (15 mg) was dissolved in    
0.2 M aq. NaCl (3 mL) and loaded on top of a column. Elution with 0.2 M aq. 
NaCl with applied pressure on top of the column afforded formation of two 
distinct orange bands. The two separate fractions were collected. Each fraction 
was desalted by loading onto C18 Sep-Pak cartridges (Waters), washed with 
H2O (~ 200 mL each) and further eluted with MeOH (10 mL). The solutions 
were concentrated and addition of diethyl ether afforded brown precipitates, 
which were filtered off, washed with diethyl ether and dried in vacuo. The two 
samples were analyzed by UV-Vis and CD spectroscopy (See chapter 3) and 
further enantiopurity was confirmed by NMR studies with Δ-TRISPHAT                    
(See chapter 4).  
 
6.2.4 Synthesis of Lo 
 
 
Ligand Lo was prepared according to the previously published method.[5] 
Pyridine-2-carboxaldehyde (0.430 g, 4 mmol) and 4,4’-diaminodiphenyl ether 
(0.400g, 2 mmol) were stirred at reflux in EtOH (50 mL) for 4h. The solution was 
cooled down and the volume was reduced to half when pale yellow solid 
precipitated. The solid was filtered off, washed with cold ethanol (50 mL) and 
dried in vacuum. Yield (0.62 g, 82 %) 
O
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1H NMR (400 MHz, CDCl3) δ = 8.72 (ddd, J = 4.9, 1.6, 0.9 Hz, 1H, H6), 8.65 (s, 
1H, H7), 8.21 (dt, J = 7.8, 0.9 Hz, 1H, H3), 7.81 (td, J = 7.7, 1.5 Hz, 1H, H4), 7.40 
- 7.32 (m, 3H, H5, 9/10), 7.10 (d, J = 8.9 Hz, 2H, H9/10) 
13C NMR (400 MHz, CDCl3) δ = 159.6 (C7), 156.3 (C11), 154.7 (C2), 149.7 (C6), 
146.2 (C8), 136.6 (C4), 125.0 (C5), 122.8 (C9/10), 121.8 (C3), 119.5 (C9/10) 
MS (ES+, CHCl3) m/z = 401.2 [M + Na]+ 
EA (%): Found: C: 76.4, H: 4.7, N: 14.6; Calc. for C24H18N4O: C: 76.2, H: 4.8,   
N: 14.8 
IR, ν (cm-1): 3048 (w), 1623 (m), 1581 (m), 1566 (m), 1493 (s), 1433 (m), 1344 
(m), 1274 (m), 1238 (s), 1195 (s), 1110 (m), 1089 (w), 1046 (m), 993 (m), 959 
(m), 858 (s), 830 (s), 775 (s), 742 (s), 715 (m), 616 (m), 582 (m). 
 
 
6.2.5 Synthesis of [Ru2Lo3]Cl4  
cis-[Ru(DMSO)4Cl2] (0.20 g, 0.41 mmol) and Lo (0.23 g, 0.62 mmol) were 
placed in a flask containing ethylene glycol (15 mL) and the flask was placed 
into a  hot oil bath (200 oC). The reaction mixture was stirred and heated under 
reflux for 7 days leading to a brown/orange solution. After cooling the solution 
was loaded directly onto a silica gel column. The compound was eluted with 
CH3CN/H2O with NH4PF6 to give an initial crude separation. The eluted orange 
band was concentrated, desalted from NH4PF6, washed with H2O and diethyl 
ether and dried in vacuo. The crude mixture was then placed onto a fresh silica 
gel column. The compound was eluted with gradient 5 to 15 mM NH4PF6 in 
CH3CN/H2O (1:3) as a second orange band following the initial red band, which 
was discarded (from colour and NMR suspected some double-stranded 
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complexes). The chloride salt of the compound was obtained by anion 
metathesis using t-Bu4NCl. Yield (26 mg, 8 %) 
Crystals suitable for X-ray analysis were obtained by slow diffusion of diethyl 
ether into CH3CN solution of the compound at 4oC.  
1H NMR (300 MHz, MeOD) δ = 9.04 (s, 1H, Him), 8.59 (d, J = 7.2 Hz, 1H, H3), 
8.39 (td, J = 7.8, 1.3 Hz, 1H, H4), 7.83 (dd, J = 9.8, 3.6 Hz, 1H, H5), 7.73 (d,      
J = 4.9 Hz, 1H, H6), 6.93 (br, 2H, HPh), 5.97 (d, J = 8.9 Hz, 2H, HPh) 
1H NMR (300 MHz, CD3CN) δ = 8.76 (s, 1H, Him), 8.48 (d, J = 7.4, 1H, H3), 8.32 
(t, J = 7.3, 1H, H4), 7.75 (t, J = 6.8, 1H, H5), 7.62 (d, J = 5.0, 1H, H6), 6.85 (br, 
2H, HPh), 5.92 (d, J = 8.7, 2H, HPh) 
MS ES+ m/z (CH3CN): 334.3 [Ru2Lo3]4+, 494.4 [Ru2Lo3](PF6)3+, 813.6 
[Ru2Lo3](PF6)22+ 
MS (ES+, CH3OH) m/z = 334.6 [Ru2Lo3]4+, 457.5  [Ru2Lo3]Cl3+ 
UV-Vis (H2O) λ max/nm, (ε /dm3 mol-1 cm-1): 270 (75 000), 322 (33 300), 445 
(15 600), 485 (21 500) 
IR, ν (cm-1): 3330 (m, br), 1589 (m), 1489 (s), 1438 (m), 1232 (s), 1198 (s), 
1163 4 (m), 866 (m), 835 (m), 767 (m), 575 (s), 565 (s) 
Crystal structure data for C72H54N12O3Ru2, 4(PF6), 0.5(C4H10O), 1.5(CH3NO2), 
0.5(C2H3N), H2O, M = 2084.46, Orthorhombic, a = 20.948(3) Å, b = 23.018(3) Å, 
c = 36.845 (4) Å, β = 90 (?)°, U = 17766(4) Å3, T = 120 (2) K, space group 
Pbca, Z = 8, 56287 reflections measured, 14615 unique (Rint = 0.1040) which 
were used in all calculations. Final R-indices (I>2σ(I)): R1 = 0.1880, wR2 = 
0.3931. 
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6.2.6 Synthesis of L2-im 
 
 
 
The ligand was synthesized following the literature procedure.[6] 
Imidazole-2-carboxaldehyde (0.384 g, 4 mmol) and 4,4’-methylenedianiline 
(0.396 g, 2 mmol) were stirred in methanol (30 mL) and two drops of glacial 
acetic acid were added. The mixture was further stirred under reflux for 2 h. An 
off-white solid that precipitated was collected by filtration, washed with methanol 
and dried in vacuo. Yield (0.68 g, 96 %) 
1H NMR (400 MHz, d6-DMSO) δ = 13.05 (s, 1H, HNH), 8.41 (s, 1H, H6), 7.45 - 
7.05 (m, 6H, H4,5,8,9), 3.99 (s, 1H, H10) 
13C NMR (400 MHz, d6-DMSO) δ = 149.88 (C6), 148.68 (C7), 144.95 (C10), 
139.42 (C7), 130.67 (C4), 129.57 (C8/9), 121.11 (C8/9), 120.13 (C5), 40.07 (C11). 
MS (ES+, DMSO) m/z = 377.2 [M + Na]+  
EA (%): Found: C: 71.1, H: 4.9, N: 23.6; Calc. for C21H18N6: C: 71.2, H: 5.1,      
N: 23.7 
IR, ν (cm-1): 3048 (w), 1624 (m), 1581 (w), 1493 (m), 1433 (m), 1238 (m), 1196 
(m), 1110 (m), 1047 (w), 993 (m), 858 (m), 830 (s), 774 (s), 756 (s), 743 (s), 716 
(m), 617 (m). 
 
 
 
N N
H
N
N N
H
N2
4
5
6 7
8
9
10
11
C21H18N6
FW: 354.4
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6.2.7 Synthesis of [Ru2L2-im3]Cl4 
cis-[Ru(DMSO)4Cl2] (0.273 g, 0.564 mmol) and L2-im (0.300 g, 0.846 mmol) in 
ethylene glycol (35 mL) were stirred at reflux under argon atmosphere for 6 
days. After cooling to room temperature a saturated aqueous solution of 
NH4PF6 was added (10 mL) and the solution was left overnight in the fridge. 
The brown solid was filtered off, washed with water (300 mL) and diethyl ether 
and dried in vacuo. The crude was then dissolved in CH3CN (10 mL) and re-
precipitated with Et2O. The precipitate was filtered off washed with Et2O and 
dried in vacuo.  The crude compound was then placed in 500 ml beaker and 
EtOH was added (400 mL). This was stirred at room temperature for 1 hour.  
The solution was filtered off and the orange filtrate was concentrated under 
reduced pressure. The concentrated solution was then loaded onto a fresh 
silica gel column. The pure compound was eluted as a second orange band 
with 5 mM NH4PF6 in CH3CN. Yield (1.7 mg, 1 %) 
Brown/orange crystals of the hexafluorophosphate salt suitable for X-Ray 
analysis were obtained by slow diffusion of diethyl ether into a CH3CN solution 
of compound. 
1H NMR (400 MHz, CD3CN) δ = 11.98 (s, 1H, HNH), 8.37 (s, 1H, Him), 7.69 (dd, 
J = 2.8, 1.4 Hz, 1H, H4), 6.93 (d, J = 8.0 Hz, 2H, HPh), 6.73 (t, J = 1.2, 0.9 Hz, 
1H, H5), 5.79 (d, J = 8.5 Hz, 2H, HPh), 4.01 (s, 1H, HCH2) 
MS ES+(CH3CN) m/z = 316.5 [Ru2L2-im3]4+, 632.5 [Ru2L2-im3]2+  
UV-Vis (H2O) λ max/nm, (ε/dm3 mol-1 cm-1): 297 (48 300), 470 (24 100) 
IR, ν (cm-1): 3025 (m, br), 1627 (w), 1536 (m), 1502 (m), 1433 (s), 1335 (m), 
1259 (w), 1194 (m), 1008 (s), 1016 (m), 895 (m), 860 (m), 762 (s), 709 (m)  
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Crystal structure data for C63H54N18Ru2, 4(PF6), 4(C2H6OS), 4(H2O),                  
M = 2229.84, Monoclinic, a = 34.894(2) Å, b = 13.3476(4) Å, c = 23.2616(12) Å, 
β = 125.597(2)°, U = 8809.6(7) Å3, T = 120 (2) K, space group C 2/c, Z = 4, 
35588 reflections measured, 9016 unique (Rint = 0.0918) which were used in all 
calculations. Final R-indices (I>2σ(I)): R1 = 0.0735, wR2 = 0.1681. 
 
6.2.8 Synthesis of L4(5)-im 
 
 
 
The compound was prepared following the literature procedure.[7] 
4(5)-imidazolecarboxaldehyde (0.288 g, 3.0 mmol), 4,4’-methylenedianiline 
(0.300 g, 1.5 mmol) and 1 drop of glacial acetic acid were stirred at reflux in 
methanol (30 mL) for 2h. An off-white solid that precipitated was collected by 
vacuum filtration, washed with methanol (30 mL) and dried in vacuo.            
Yield (0.52 g, 97 %) 
1H NMR (400 MHz, d6-DMSO) δ = 12.8 (s, 1H, HNH), 8.43 (s, 1H, H6), 7.82 (s, 
1H, H2/4), 7.62 (s, 1H; H2/4), 7.22 (d, J = 7.8 Hz, 2H, H8/9), 7.16 (d, J = 7.8 Hz, 
2H, H8/9), 3.98 (s, 1H, H11) 
13C NMR: compound not soluble enough 
MS (ES+, DMSO) m/z = 377.2 [M + Na]+  
EA (%): Found: C: 70.9, H: 5.2, N: 23.7; Calc. for C21H18N6: C: 71.2, H: 5.1,       
N: 23.7 
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IR, ν (cm-1): 1350 (w), 1625 (m), 1581 (m), 1494 (s), 1433 (m), 1345 (w), 1239 
(s), 1225 (m), 1197 (s), 1110 (m), 1091 (m), 1047 (w), 994 (m), 974 (m), 859 
(m), 830 (s), 775 (s), 716 (m), 618 (s).  
 
 
6.2.9 Synthesis of [Ru2L4(5)-im3]Cl4  
cis-[Ru(DMSO)4Cl2] (0.273 g, 0.564 mmol) and L4(5)-im (0.300 g, 0.846mmol) 
were placed in the flask containing ethylene glycol (20 mL) and the flask was 
placed into a hot oil bath (200 oC). The reacting mixture was stirred under reflux 
for 6 days when the brown/orange solution formed. After cooling the saturated 
aqueous solution of NH4PF6 (10 mL) was added and the precipitate that formed 
was filtered off, washed with water (200 mL) and dried in vacuo. The crude was 
then dissolved in CH3CN (10 mL) and reprecipitated with diethyl ether. The dark 
brown solid was filtered off, washed with diethyl ether and dried in vacuo. The 
compound was extracted with ethanol and further purified on the fresh silica gel 
column with CH3CN/15mM aq NH4PF6 (3:1). The pure compound was eluted as 
a second orange band.  The counterion was then exchanged to chloride using  
t-Bu4NCl. Yield (1.9 mg, 1 %)  
1H NMR (300 MHz, MeOD) δ = 8.42 (s, 1H, H6), 8.25 (s, 1H, H4/2), 7.59 (s, 1H, 
H4/2), 6.94 (d, J = 7.6, 1H, H8/9), 5.76 (d, J = 8.0, 1H, H8/9), 3.98 (s, 1H, H11) 
MS ES+ (MeOH) m/z = 316.4 [Ru2L4(5)-im3]4+, 421.9 [Ru2L4(5)-im3 – H]3+, 632.2 
[Ru2L4(5)-im3 – 2H]2+ 
UV-Vis (H2O) λ max/nm, (ε/dm3 mol-1 cm-1): 423 (21 000) 
IR, ν (cm-1): 3128 (m, br), 1961 (w), 1673 (s), 1596 (m), 1501 (m), 1279 (m), 
1201 (s), 1130 (s), 799 (s), 720 (s). 
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6.2.10 Synthesis of Lox 
 
 
4-oxazolecarboxaldehyde (0.097 g, 1 mmol) and 4,4’-methlenedianiline      
(0.099 g, 0.5 mmol) were stirred in ethanol (50 mL) at room temperature for 4 
hours. The volume was reduced to half and the solution was left in the fridge for 
2h. The resultant yellow precipitate that formed was filtered off, washed with 
ethanol and dried in vacuo. Yield (0.114 g, 64 %) 
1H NMR (400 MHz, CDCl3) δ = 8.47 (s, 1H, H6), 8.21 (d, J = 0.6, 1H, H2/4), 7.99 
(d, J = 0.4, 1H, H2/4), 7.27 - 7.18 (m, 4H, H8&9), 4.03 (s, 1H, H11) 
13C NMR (400 MHz, CDCl3) δ = 151.62 (C2/4), 150.30 (C6), 149.35 (C10), 140.23 
(C2/4), 139.52 (C7), 139.22 (C5), 129.7 (C8/9), 121.14 (C8/9), 41.01 (C11) 
MS (ES+): m/z = 379.1 [M + Na]+  
HRMS (ES+) m/z: Found: 379.1158, Calc. for C21H16N4O2Na: 379.1165 
EA (%): Found: C: 70.8, H: 4.5, N: 15.7; Calc. for C20H16N4O2: C: 70.8, H: 4.5, 
N: 15.7  
IR, ν (cm-1): 3460 (w), 3085 (w), 1727 (w), 1670 (w), 1636 (m), 1574 (w), 1530 
(m), 1499 9m), 1430 (w), 1381 (w), 1293 (m), 1238 (m), 1166 (m), 1091 (m), 
1050 (m), 1073 (w), 905 (m), 864 (m), 795 (m), 755 (s), 743 (m), 699 9 (m),   
613 (s) 
mp (oC): 155 – 160. 
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6.2.11 Synthesis of L1 
 
 
 
Imidazole-2-carboxaldehyde (0.192 g, 2.0 mmol) and p-xylenediamine        
(0.136 g, 1.0 mmol) were stirred in methanol (30 ml) for 30 min, 1 drop of glacial 
acetic acid was added and the reacting mixture was stirred at reflux for further 2 
hours. An off white solid that precipitated was collected by vacuum filtration, 
washed with methanol (20 mL) and dried in vacuo. Yield (0.26 g, 89 %) 
1H NMR (400 MHz, d6-DMSO) δ = 12.73 (s, 1H, HNH), 8.31 (s, 1H, H6), 7.32 (s, 
2H, H9), 7.21 (s, 1H, H4/5), 7.08 (s, 1H, H4/5), 4.77 (d, J = 1.2, 2H, H7) 
13C NMR: compound not soluble enough 
MS (ES+): m/z = 293.2 [M + H]+  
EA (%): Found: C: 65.9, H: 5.3, N: 28.8; Calc. for C16H16N6: C: 65.7, H: 5.5,      
N: 28.8 
IR, ν (cm-1): 3009 (w, br), 2883 (w, br), 2770 (w, br), 1645 (s), 1557 (w), 1457 
(m), 1444 (s), 1418 (m), 1388 (m), 1348 (m), 1304 (m), 1109 (m), 1044 (m), 
1002 (m), 988 (m), 909 (s), 823 (m), 804 (s), 770 (s), 752 (s) 
mp (oC): 222 – 234 (decomposition). 
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6.2.12 Synthesis of L2 
 
 
 
Pyridine-2-carboxaldehyde (0.214 g, 2.0 mmol) and p-xylenediamine (0.136 g, 
1.0 mmol) were stirred in ethanol (30 mL) at 60oC for 2h. The solution was 
cooled down to room temperature and then left in the fridge for 3h. The 
crystalline material that formed was then re-crystallized from ethanol. The white 
crystalline compound was filtered off washed with cold ethanol (5 mL) and dried 
in vacuo. Yield (0.21 g, 67 %) 
1H NMR (400 MHz, CDCl3) δ = 8.66 (dd, J = 4.8, 0.7 Hz, 1H, H6), 8.50 (s, 1H, 
H7), 8.07 (d, J = 7.9 Hz, 1H, H3), 7.75 (t, J = 7.7 Hz, 1H, H4), 7.39 - 7.30 (m, 3H, 
H5,Ph), 4.89 (d, J = 0.9 Hz, 2H, H8) 
13C NMR (400 MHz, CDCl3) δ = 162.78 (C6), 154.54 (C2), 149.38 (C4), 137.61 
(C9), 136.56 (C7), 128.46 (C10), 124.82 (C5), 121.35 (C3), 64.65 (C8)   
MS (ES+) m/z = 337.2 [M + Na]+  
HRMS (ES+) m/z = Found: 337.1433, Calc. for C20H18N4Na: 337.1424 
EA (%): Found: C: 76.5, H: 5.6, N: 17.7; Calc. for C20H18N4: C: 76.4, H: 5.8,      
N: 17.8 
IR, ν (cm-1): 3049 (w), 2903 (w), 1698 (m), 1639 (m), 1587 (m), 1565 (m), 1512 
(m), 1470 (m), 1434 (m), 1358 (m), 1322 (m), 1194 (w), 1150 (w), 1090 (w), 
1045 (m), 1015 (m), 990 (m), 981 (m), 916 (w), 896 (w), 848 (s), 775 (s), 754 
(m), 738 (m), 662 (m), 616 (s), 571 (s) 
mp (oC): 122-123. 
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6.2.13 Synthesis of La 
 
 
Ligand L was prepared according to literature procedures.[6, 8] 
2-Nitrosopyridine (0.24 g, 2.2 mmol) was dissolved in 30 ml of dichloromethane. 
4,4’-methylenedianiline (0.20 g, 1.0 mmol) and one drop of glacial acetic acid 
were added and the orange solution was stirred at room temperature for 2 days. 
The solvent was evaporated to dryness and the crude product was purified by 
column chromatography on a silica gel column with CHCl3/MeOH (98/2).      
Yield (0.26 g, 68 %)  
1H NMR (400 MHz, CDCl3) δ = 8.63 (ddd, J = 4.8, 1.8, 0.8, 1H, H6), 7.92 (d, J = 
8.4, 2H, H8/9), 7.77 (ddd, J = 7.8, 1.9, 0.6, 1H, H4), 7.71 (dt, J = 8.1, 1.0, 1H, 
H3), 7.32 - 7.25 (m, 3H, H8/9&5), 4.04 (s, 1H, H11) 
13C NMR (400 MHz, CDCl3) δ = 162.92 (C2/7/10), 151.1 (C2/7/10), 149.52 (C6), 
144.85 (C2/7/10), 136.31 (C4), 129.79 (C8/9), 125.14 (C5), 123.96 (C8/9), 115.52 
(C3), 41.77 (C11) 
MS (ES+) m/z = 401.2 [M + Na]+  
EA (%): Found: C: 73.1, H: 4.3, N: 22.2; C: Calculated for C23H18N6: C: 73.0,     
H: 4.8, N: 22.2 
IR, ν (cm-1): 3063 (w), 1578 (m), 1499 (m), 1461 (m), 1412 (s), 1309 (w), 1218 
(w), 1184 (w), 1134 (m), 1110 (m), 1113 (w), 989 (m), 873 (m), 840 (m), 820 
(m), 791 (s), 737 (s), 657 (m), 640 (m), 618 (s), 576 (s), 554 (s). 
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6.2.14 Synthesis of [Ru2La(NH3)8]Cl4 
[Ru(NH3)5(H2O)](PF6)2 (100 mg, 0.2 mmol) and L (38 mg, 0.1 mmol) were 
dissolved in an argon-purged acetone (15 mL) and the reaction mixture was 
stirred at room temperature under an argon atmosphere for 18h. The solution 
was filtered off, saturated solution of t-Bu4NCl (5 mL) was added to the filtrate 
and the red precipitate was filtered off, washed with acetone (50 mL) and 
diethyl ether and dried in vacuo. Purification was performed on an alumina 
column with CH3CN/H2O 80/20 as an eluent. The compound was eluted as a 
third band. Yield (56 mg, 62 %) 
Crystals suitable for X-Ray analysis (needles) were obtained by slow diffusion 
of Et2O into a methanolic solution of the compound.  
1H NMR (300 MHz, MeOD) δ = 8.81 (d, J = 5.3 Hz, 1H, H6), 8.53 (d, J = 7.7 Hz, 
1H, H3), 8.02 (ddd, J = 7.4, 5.8, 1.4, 1H, H4), 7.76 (ddd, J = 7.3, 5.9, 1.3, 1H, 
H5), 7.70 (d, J = 8.5 Hz, 2H, H8/9), 7.62 (d, J = 8.5 Hz, 2H, H8/9), 4.30 (s, 1H, 
H11) 
MS ES+ (CH3OH): m/z = 250.1 [Ru2La(NH3)8]Cl3+, 245.2 [Ru2La(NH3)7]Cl3+, 
239.1 [Ru2La(NH3)6]Cl3+, 233.3 [Ru2La(NH3)5]Cl3+, 358.4 [Ru2La(NH3)8]2+ 
EA (%): Found: C: 31.9, H: 4.7, N: 22.8; Calc. for Ru(C23H18N4)(NH3)8Cl4,        
C: 32.2, H: 4.9, N: 22.8 
UV-Vis (H2O) λ max/nm, (ε/dm3 mol-1 cm-1): 227 (22900), 333 (20400), 478 
(9000). 
IR, ν (cm-1): 3141 (s, br), 1623 (s), 1598 (m), 1455 (m), 1280 (s), 1244 (m), 
1202 (m), 771 (s), 619 (s)  
Crystal structure data for C23H42N14Ru2, 4(Cl), 2(CH3OH), 0.7(H2O):                  
M = 935.34, Monoclinic, a = 21.6832 (6) Å, b = 7.4548 (2) Å, c = 25.3399 (7) Å,        
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β = 94.048 (1)°, U = 4085.8 (2) Å3, T = 120 (2) K, space group P21/c (no. 14), Z 
= 4, 59791 reflections measured, 7188 unique (Rint = 0.1277) which were used 
in all calculations. Final R-indices (I>2σ(I)): R1 = 0.0869, wR2 = 0.1909 
Crystal structure data for C23H42N14Ru2, 4(PF6), 4(H2O): M = 1368.79, 
Monoclinic, a = 16.9517 (9) Å, b = 14.4634 (7) Å, c = 38.9319 (18) Å, β = 
91.194 (3)°, U = 9543.2(8) Å3, T = 120 (2) K, space group P2(1)/n, Z = 8, 73837 
reflections measured, 16442 unique (Rint = 0.1377) which were used in all 
calculations. Final R-indices (I>2σ(I)): R1 = 0.0872, wR2 = 0.1983. 
 
 
6.2.15 Synthesis of [RuLa(NH3)4]Cl2  
[Ru(NH3)5(H2O)](PF6)2 (100 mg, 0.2 mmol) and L (76 mg, 0.2 mmol) were 
dissolved in argon-purged acetone (20 mL) and the reaction mixture was stirred 
at room temperature under argon atmosphere for 18h. A saturated acetone 
solution of t-Bu4NCl was added (5 mL) and the formed precipitate was filtered 
off, washed with acetone (50 mL) and dried in vacuo. Purification was 
performed on an alumina column with CH3CN/H2O 80/20 as an eluent. The 
compound was eluted as a second orange band. Yield (68 mg, 55 %)  
Crystals suitable for X-ray analysis were obtained by slow diffusion of Et2O into 
a methanolic solution of the compound (crystals of chloride salt) and by slow 
evaporation of CH3CN from the mixture H2O/CH3CN (crystals of 
hexafluorophosphate salt). 
1H NMR (500 MHz, 300K, MeOD) δ = 8.80 (d, J = 5.6 Hz, 1H, H6), 8.70 (dd,      
J = 4.7, 0.9 Hz, 1H, H6’), 8.52 (d, J = 8.1 Hz, 1H, H3), 8.10 (td, J = 7.9, 1.7 Hz, 
1H, H4’), 8.01 (m, 3H, HPh&4), 7.89 (d, J = 8.1 Hz, 1H, H3’), 7.75 (ddd, J = 6.5, 
 164 
1.1 Hz, 1H, H5), 7.67 (d, J = 8.4 Hz, 2H, HPh), 7.62 – 7.55 (m, 5H, H5’&Ph), 4.27 
(s, 2H, H11); 
13C NMR (500 MHz, 300K, MeOD) δ = 171.00 (C2), 164,00 (C2’), 157.72 (C7/7’), 
152.40 (C7/7’), 151.50 (C6), 150.05 (C6’), 147.42 (C10/10’), 143.82 (C10/10’), 140.71 
(C4’), 138.51 (C4), 131.22 (2CPh), 131.11 (2CPh), 127.09 (C5’), 124.86 (2CPh), 
124.38 (C5), 124.18 (2CPh), 123.88 (C3), 115.74 (C3’), 42.30 (C11) 
MS ES+ (MeOD) m/z = 273.8 [RuLa(NH3)4]2+, 256.5 [RuLa(NH3)4]2+, 240.1 
[RuLa(NH3)2]2+ 
IR, ν (cm-1): 2961 (w), 1725 (s), 1515 (m), 1438 (m), 1403 (m), 1300 (m), 1247 
(m), 1231 (m), 1181 (m), 1110 (w), 1155 (w), 1030 (w), 971 (w), 829 (m), 800 
(m), 787 (m), 775 (m), 716 (w) 
Crystal structure data for C23H30N10O3Ru, 2(Cl), 0.25(C2H3N), 3(H2O), M = 
682.85, Orthorhombic, a = 11.6956(2) Å, b = 31.2498(8) Å, c = 8.4504(2) Å, β = 
90°, U = 3088.50(12) Å3, T = 120(2) K, space group P cc2, Z = 4, 18785 
reflections measured, 4728 unique (Rint = 0.0588) which were used in all 
calculations. Final R-indices (I>2σ(I)): R1 = 0.0577, wR2 = 0.1541. 
 
 
6.2.16 Synthesis of (E)-2-(phenyldiazenyl)pyridine, Lazpy 
 
2-nitrosopyridine (0.216 g, 2 mmol), aniline (0.186 g, 2 mmol) and one drop of 
glacial acetic acid were stirred in dichloromethane (30 mL) for 12 h. The 
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solution was concentrated and the crude product was purified by column 
chromatography on silica gel with CHCl3 as an eluent.  The compound was 
eluted as a second intensive orange band. Yield (0.27 g, 73.8 %)  
1H NMR (400 MHz, CDCl3) δ = 8.72 (ddd, J = 4.8, 1.8, 0.8, 1H, H6), 8.05 (ddd,   
J = 5.2, 4.3, 1.9, 2H, H8/9), 7.87 (ddd, J = 8.0, 7.3, 1.8, 1H, H4), 7.81 (dt, J = 8.0, 
1.0, 1H, H3), 7.55 - 7.48 (m, 3H, H10&8/9), 7.37 (ddd, J = 7.2, 4.8, 1.2, 1H, H5) 
13C NMR (400 MHz, MeOD) δ= 162.85 (C2), 152.4 (C7), 149.5 (C6), 138.35 (C4), 
132.2 (C10), 129.15 (C8/9), 125.2 (C5), 123.6 (C8/9), 115.55 (C3) 
MS (ES+) m/z = 206.1 [M + Na]+  
EA (%): Found: C: 72.2, H: 4.9, N: 22.9; Calc. for C11H9N3: C: 72.1, H: 4.95,     
N: 22.9.  
IR, ν (cm-1): 3061 (w), 1578 (s), 1492 (m), 1462 (m), 1416 (s), 1304 (w), 1261 
(w), 1217 (w), 1182 (w), 1136 (m), 1090 (w), 989 (m), 920 (w), 787 (s), 735 (s), 
681 (s), 621 (m), 577 (w), 552 (s) 
 
 
6.2.17 Synthesis of [RuLazpy(NH3)4]Cl2  
[Ru(NH3)5(H2O)](PF6)2 (15 mg, 0.03 mmol) and Lazpy (11 mg, 0.03 mmol) were 
stirred in acetone (15 mL) under an argon atmosphere for 18h. The red solution 
was filtered off and the filtrate was concentrated under reduced pressure. 
Addition of diethyl ether afforded an orange/red precipitate, which was filtered 
off, washed with diethyl ether and dried in vacuo. The chloride salt of the 
compound was obtained by anion metathesis using t-Bu4NCl.  
Yield (11.3 mg, 29 %)  
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Red, needle-shaped crystals of hexafluorophosphate salt suitable for X-ray 
diffraction were obtained by slow diffusion of benzene into CH3CN solution of 
the compound.  
1H NMR (300 MHz, MeOD) δ = 8.76 (ddd, J = 5.8, 1.3, 0.6 Hz, 1H, H6), 8.53 
(ddd, J = 8.2, 1.3, 0.7 Hz, 1H, H3), 8.01 (ddd, J = 8.2, 7.4, 1.5 Hz, 1H, H4), 7.75 
(ddd, J = 7.3, 5.9, 1.4 Hz, 1H, H5), 7.69 – 7.60 (m, 5H, H8,9,10) 
MS ES+ (CH3OH) m/z = 320.1 [RuLazpy]Cl+, 354.1 [RuLazpy(NH3)2]Cl+, 371.1 
[RuLazpy(NH3)3]Cl+, 388.2 [RuLazpy(NH3)4]Cl+ 
EA (%): Found: C: 31.3, H: 4.7, N: 23.1; Calc. for Ru(C11H9N3)(NH3)4Cl2:          
C: 31.2, H: 5.0, N: 23.1 
UV-Vis (H2O) λ max/nm, (ε/dm3 mol-1 cm-1): 223 (10 500), 323 (10 000),         
477 (4 300) 
IR, ν (cm-1): 3100 (s, br), 1639 (m), 1463 (m), 1450 (m), 1278 (s), 1248 (m), 
1198 (m), 771 (s), 706 (s)  
Crystal structure data for C11H21N7Ru, C6H6, 2(PF6): M = 720.47, Monoclinic, a 
= 16.338(4) Å, b = 10.733(3) Å, c = 16.797(4) Å, b= 115.673(14)°, U = 
2654.6(11) Å3, T = 120 (2) K, space group P 2(1)/n, Z = 4, 22120 reflections 
measured, 4646 unique (Rint = 0.1395) which were used in all calculations. Final 
R-indices (I>2σ(I)): R1 = 0.1359, wR2 = 0.2959. 
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6.3 DNA binding studies 
6.3.1 Materials and methods 
Calf-thymus DNA (highly polymerized ct-DNA) was purchased from Sigma 
Aldrich and used as received. The stock solutions of DNA were prepared by 
dissolving the fibers in ultrapure water (1 mg per 1 mL of H2O) and the aliquots 
were stored at -20 oC. Solutions with the required DNA concentrations were 
always freshly prepared from the stock samples on the day of the experiment 
and retained in ice until needed. The final concentration of DNA was 
determined by UV-Vis spectroscopy on the basis of the extinction coefficient of                 
ε258 = 6600 mol-1 dm3 cm-1 per DNA base.[9] Solutions of DNA gave an 
absorbance ratio at 260 nm and 280 nm, A260/A280, of ~1.8, implying that the 
DNA was satisfactorily free from proteins.  
All DNA binding experiments were performed at 25oC in buffer containing         
20 mM NaCl and 1 mM sodium cacodylate. Ultrapure water (Sigma Aldrich) 
was used in all experiments.  
Stock solutions of ruthenium(II) compounds (600 µM) were prepared by 
dissolving the chloride form of the complex in milli-Q water. 
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6.3.2 Circular and linear dichroism 
Circular dichroism and linear dichroism measurements were conducted using a 
Jasco J-810 spectropolarimeter. Experiments were carried out at a constant 
DNA concentration (300 µM) in the buffer containing 20 mM sodium chloride 
and 1 mM sodium cacodylate, pH 6.8. During the titration the concentration of 
the complex in the sample was gradually increased from 5 µM to 50 µM, which 
corresponds to DNA base to complex ratios ranging from 60:1 to 6:1. 
 
CD spectra were obtained using a 10 mm pathlength cuvette in the range of 
700 to 300 nm and 2 or 1 mm pathlength cuvette for the 300 - 200 nm range.  
Parameters: Sensitivity – standard (100 mdeg), Data pitch – 0.5 nm, Scanning 
mode – continuous, Scanning speed – 200 nm/min, Response – 1 sec, Band 
width – 1 nm, Accumulation - 12 
Linear dichroism spectra were recorded using a flow Couette cell with a total 
pathlength of 1 mm.  
Parameters: Sensitivity – Standard (0.1 dOD), Data Pitch: 0.5 nm, Scanning 
mode – continuous, Scanning speed – 500 nm/min, Response – 0.25 sec, Band 
width – 2 nm, Accumulation – 8  
During both CD and LD titration experiments the HT value was kept below     
600 V. [10]  
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6.3.3 Agarose gel experiments 
Plasmid pBR322 was purchased from New England Biolabs, agarose powder 
was purchased from Bioline. 
The samples were prepared as follows: Plasmid pBR322, 1 µL of 1 µg mL-1 
stock solution, was mixed with varying amounts of complex and ultrapure water 
to give a final volume of 16 µL. The volume of the complex added (stock 
solution 60 µM) varied from 1.28 µL at the ratio of 20 base pairs to 1 complex to 
12.83 µL at ratio 2 : 1. The prepared solutions were incubated for 1 h at 37oC. 
After incubation the loading buffer (30% glycerol, 0.05% bromophenol blue and 
0.025 % cyanol xylene in ultrapure water) was added (4 µL) and the solutions 
were vortex and gently centrifuged.  
1 % agarose gel was prepared by melting 2 g of agarose in 200 mL of 1 x TAE 
buffer, poured into the tray and left to set for 30 min. 16 µL aliquots were  
loaded into wells (first and last well were control samples). The gel was run in a 
1 x TAE buffer for 2.5 h at 5 V cm-1. After electrophoresis the gel was stained in 
a TAE solution of ethidium bromide (0.5 µg mL-1) for 30 min. Visualisation of the 
agarose gels was performed at 312 nm using a UVIPro Platinum system 
(UVIDoc, Cambridge, UK). 
 
6.3.4 Thermal denaturation  
ct-DNA thermal denaturation experiments were performed on Cary 5000 Varian 
spectrophotometer in a buffer containing 20 mM sodium chloride and 1 mM 
sodium cacodylate. The measurements were carried out in the range of 
temperatures 25 – 95 oC with heating speed 1 oC/min. The analysis of the DNA 
denaturation profiles was performed using the derivative method. 
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6.4 Cell tests  
RPMI, DMEM, FBS, L-glutamine, HEPES, sodium pyruvate, and 10% trypsin-
EDTA were purchased from Invitrogen. Antibiotic-actinomycin solution,            
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and DMSO 
were obtained from Sigma Aldrich. 
Cells were cultured in RPMI (T47D) or DMEM (MDA-MB-231) medium 
supplemented with 10 % FBS, 1 % L-glutamine, 1 % HEPES buffer, 1 % 
sodium pyruvate and 1 % antibiotic. Cells were harvested by trypsinisation at 
80-90 % confluence.  
The MTT assay was performed as follows: 8000 cells/well (MDA-MB-231, T47-
D) were seeded in a 96-well microtiter plate (Costar) and incubated at 37oC for 
24h to adhere. The following day the cells were treated with a range of 
concentrations of tested compound prepared in an appropriate medium (the 
concentrations applied were individual for each Ru complex) and the cells were 
incubated at 37oC (5 % CO2 atmosphere) for 72 hours. This was followed by an 
addition of 20 µL of MTT solution in PBS (5 mg/mL) into each well (except for 4 
control wells) and incubation of plates for a further 3 hours. The medium was 
removed and 100 µL of DMSO added. The plates were covered with aluminum 
foil and gently shaken for 30 min. Optical density was determined using a 
microplate reader (BioRad) operating at 590 nm. 
The assay was repeated three or four times for each compound. The IC50 
values were determined from concentration-response curves.  
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Conclusions and Future Perspectives 
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Supramolecular chemistry has proven to be a powerful tool in the design 
of novel DNA-binding therapeutic agents.  
 
Supramolecular ruthenium triple-stranded helicates presented in chapter 
2 have been shown to bind to DNA and alter its secondary structure by bending 
and unwinding the double helix. Although, as it has been shown previously, the 
DNA recognition properties of the cylinders can be ‘tuned’ by introducing 
modifications e.g. substituents in the cylinders building moieties, the work 
presented in chapter 2 showed that simply by changing the metal binding units 
in the helicates, while maintaining the overall size and shape of the cylinder, the 
binding properties of these compounds can change dramatically. Excitingly, 
these discrete changes in the structure of the helicate i.e. using imidazole 
instead of pyridine in the ligand, led to a considerable increase in the 
cytotoxicity of the helical drugs.  
Chapters 3 and 4 are focused on chiral recognition between the supramolecular 
cylinders and biomolecules as well as within small molecule systems. It has 
been shown that the two optical isomers of ruthenium cylinder interact 
differently with DNA and with Δ-TRISPHAT. Indeed, the interaction of the 
cylinders within the two systems is driven by molecular shape ‘compatibility’ and 
the recognition of DNA by chiral helicates appears to be a function of multiple 
events, which all together lead to severe structural changes in the biomolecule. 
These are naturally distinctive and characteristic for each enantiomer.  
 
Chapter 5 focuses on combining the moieties of supramolecular cylinders, 
ammine drugs and ruthenium azopyridine complexes in order to achieve 
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integrated effects of these drugs. The three complexes consisting of the above 
building units have been successfully prepared and characterised. Moreover, 
the DNA binding studies on the dinuclear tetracationic Ru complex and its 
mononuclear analogue showed that the dinuclear complex has a much greater 
potential to interact with the biomolecule. This could be due to a number of 
factors, such as the potential of the complex for electrostatic attractions or 
hydrophobic interactions.  
 
Understanding molecular insights of the drug-DNA recognition processes 
is of crucial importance for rational drug design and future development of 
novel, superior therapeutics. In this context, in order to better understand the 
forces that drive the recognition processes and also to understand the cellular 
outcomes of our drugs binding to DNA, future work on the systems presented in 
this thesis should include exhaustive studies of the DNA recognition processes 
at the structural, electronic, thermodynamic and kinetic level.  
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S1. Lipophilicity of ruthenium triple-stranded helicates 
 
 
Compound P log P 
[Ru2L3]Cl4 0.099 -0.96 ± 0.07 
[Ru2Lo3]Cl4 0.0150 -0.88 ± 0.12 
 
Table S1 Octanol-water partition coefficients for Ru(II) triple-stranded helicates; (each value 
represents the average of the values obtained from three independent experiments, errors 
represent standard deviations) 
 
The partition coefficient (P) of the complex between n-octanol and water was 
determined using shake-flask method.[1] All measurements were carried out at 
room temperature. N-octanol and water were saturated one with another and 
equilibrated for 24 h before experiment. The absorption spectra were recorded 
using a Cary 5000 Varian spectrophotometer.  
Aliquots of working solutions of ruthenium complexes were added to equal 
volumes of n-octanol and shaken in a mechanical shaker (IKA Vibrax VXR 
basic) for 3h at 1000 1/min. The solutions were then left to equilibrate for one 
hour, the organic and aqueous layers were then carefully separated and the 
UV-Vis spectra of the aqueous layer before and after partition were recorded. 
Experiments were carried out in triplicate for two or three different 
concentrations of the compounds. The partition coefficients were calculated 
using the equation: logPoct = log[(A1-A2)/A2], where A1 and A2 – UV-Vis 
absorption values of the compound at the aqueous phase before and after 
partition respectively.  
 
 
 
                                                
[1] J. Sangster, Octanol-Water Partition Coefficients: Fundamentals and Physical Chemistry, Vol. 
2, John Wiley & Sons, New York, 1997. 
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S2. 2D NMR spectrum of [RuLa(NH3)4]Cl2 
 
 
 
 
 
 
Fig. S1 1H-1H COSY NMR spectrum of  [RuLa(NH3)4]Cl2 in MeOD. 
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S3. UV-Vis spectra of [Ru2La(NH3)8]Cl4 and [RuLazpy(NH3)4]Cl2 in H2O 
 
 
 
 
 
Fig. S2 UV-Vis absorption spectra of (left) [Ru2La(NH3)8]Cl4 and (right) [RuLazpy(NH3)4]Cl2 in 
aqueous solution recorded at room temperature. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
